<SEC-DOCUMENT>0000049071-25-000021.txt : 20250430
<SEC-HEADER>0000049071-25-000021.hdr.sgml : 20250430
<ACCEPTANCE-DATETIME>20250430060550
ACCESSION NUMBER:		0000049071-25-000021
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20250430
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250430
DATE AS OF CHANGE:		20250430

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HUMANA INC
		CENTRAL INDEX KEY:			0000049071
		STANDARD INDUSTRIAL CLASSIFICATION:	HOSPITAL & MEDICAL SERVICE PLANS [6324]
		ORGANIZATION NAME:           	02 Finance
		EIN:				610647538
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-05975
		FILM NUMBER:		25890659

	BUSINESS ADDRESS:	
		STREET 1:		500 W MAIN ST
		CITY:			LOUISVILLE
		STATE:			KY
		ZIP:			40202
		BUSINESS PHONE:		5025801000

	MAIL ADDRESS:	
		STREET 1:		500 W. MAIN ST
		CITY:			LOUISVILLE
		STATE:			KY
		ZIP:			40202

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXTENDICARE INC
		DATE OF NAME CHANGE:	19740404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HERITAGE HOUSE OF AMERICA INC
		DATE OF NAME CHANGE:	19671129
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>hum-20250430.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:e5e9e503-258c-45f1-8531-8025894f3404,g:1fbfcee5-b4be-4719-90c1-a5050312e034,d:502a55475a4e432dbc4d5c7a2606d6c5-->
<html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>hum-20250430</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0000049071</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-22">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="hum-20250430.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i502a55475a4e432dbc4d5c7a2606d6c5_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.861%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, DC&#160;20549</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.527%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="15" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.527%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="15" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Exchange Act of 1934</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported):&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">April 30, 2025</ix:nonNumeric> (April 30, 2025)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.472%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Humana Inc.</ix:nonNumeric> </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.194%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exact name of registrant as specified in its charter)</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.750%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">1-5975</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">61-0647538</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">500 West Main Street</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Louisville</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-9">KY</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">40202</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">502</ix:nonNumeric>-<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">580-1000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.472%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> General Instruction A.2. below):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.150%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17&#160;CFR&#160;230.425)</span></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.150%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.150%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17&#160;CFR&#160;240.14d-2(b))</span></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.150%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17&#160;CFR&#160;240.13e-4(c))</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:36.591%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.517%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">HUM</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i502a55475a4e432dbc4d5c7a2606d6c5_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div id="i502a55475a4e432dbc4d5c7a2606d6c5_10"></div><div style="-sec-extract:summary;margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item&#160;7.01&#160;&#160;&#160;&#160;Regulation FD Disclosure.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humana Inc. (the "Company") issued a press release this morning reporting financial results for the quarter ended March 31, 2025, and posted a detailed earnings release related to the same period to the Investor Relations portion of the Company&#8217;s website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.humana.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;A copy of each release is attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and each release is incorporated herein by reference. Additionally, a copy of management's prepared remarks on the Company's financial results for the quarter ended March 31, 2025 and expectations for future earnings, is attached hereto as Exhibit 99.3, and incorporated herein by reference.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i502a55475a4e432dbc4d5c7a2606d6c5_13"></div><div style="-sec-extract:summary;margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Exhibits:</span></div><div style="margin-bottom:1pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:6.084%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:58.137%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.612%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="hum-2025q18kxex99x1brief.htm">Press Release</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="hum-2025q18kxex99x2detailed.htm">Earnings Release and Statistical Pages</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a1q2025humanaincpreparedre.htm">Prepared Management Remarks</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="6" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i502a55475a4e432dbc4d5c7a2606d6c5_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:1pt;margin-top:12pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.456%"><tr><td style="width:1.0%"/><td style="width:13.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.651%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">HUMANA INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BY:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">/s/ John-Paul W. Felter</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">John-Paul W. Felter</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Senior Vice President, Chief Accounting Officer &amp; Controller</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Accounting Officer)</span></td></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: April 30, 2025</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>hum-2025q18kxex99x1brief.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="id6e7316dbb9e4417b1dec829e92b6aeb_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:15pt;font-weight:700;line-height:100%">n e w s</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:15pt;font-weight:400;line-height:100%">  r e l e a s e</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 99.1</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Humana Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">500 West Main Street</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">P.O. Box 1438</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Louisville, KY 40202</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">http&#58;&#47;&#47;www.humana.com</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">FOR MORE INFORMATION CONTACT&#58;</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.817%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Lisa Stoner<br>Humana Investor Relations<br>(502) 580-2652<br>e-mail&#58; LStamper&#64;humana.com</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><img alt="humanalogoa05.jpg" src="humanalogoa05.jpg" style="height:65px;margin-bottom:5pt;vertical-align:text-bottom;width:217px"></div></td></tr></table></div><div style="margin-top:7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Mark Taylor</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Humana Corporate Communications</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(317) 753-0345</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">e-mail&#58; MTaylor108&#64;humana.com</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#5c9a1b;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Humana Reports First Quarter 2025 Financial Results&#59; </font></div><div style="text-align:center"><font style="color:#5c9a1b;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Affirms Full Year 2025 Adjusted Financial Guidance</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Reports 1Q25 earnings per share (EPS) of $10.30</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on a GAAP basis,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EPS of $11.58</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">1Q25 Insurance segment benefit ratio of 87.4 percent, in line with the company's previously disclosed expectation of 'approximately 87.5 percent'</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Affirms Adjusted FY 2025 EPS guidance of 'approximately $16.25'&#59; while revising GAAP EPS to 'approximately $14.68' from the previous estimate of 'approximately $15.88'</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Affirms FY 2025 Insurance segment benefit ratio guidance range of 90.1 percent to 90.5 percent</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Affirms expected individual Medicare Advantage annual membership decline of approximately 550,000, inclusive of the impact of exiting certain unprofitable plans and counties</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">Remains confident in 2025 pricing strategy as the company prioritizes membership that is expected to drive sustainable, long-term value creation</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Continues to advance the company's long-term strategy with achievements within the CenterWell and Medicaid businesses</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.59pt">CenterWell Pharmacy selected as the fulfillment pharmacy for NovoCare</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#174;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Pharmacy&#8217;s weight loss medication for cash pay customers</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.59pt">Illinois announced its intent to award the company a contract for the state's new Fully Integrated Dual Eligible Special Needs Plan program </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Publishes prepared management remarks to Investor Relations page of www.humana.com ahead of this morning's 8&#58;00 a.m. ET question and answer session to discuss its financial results for the quarter and expectations for future earnings</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">LOUISVILLE, KY (April 30, 2025)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> &#8211; Humana Inc. (NYSE&#58; HUM) today reported consolidated pretax results and net  earnings per share (EPS) for the quarter ended March 31, 2025 (1Q25) versus the quarter ended March 31, 2024 (1Q24) as noted in the tables below.</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.666%"><tr><td style="width:1.0%"></td><td style="width:68.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.117%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.299%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated income before income taxes and equity in net losses (pretax results) </font></div><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">in millions</font></div></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1Q25 (a)</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1Q24 (a)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Generally Accepted Accounting Principles (GAAP)</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$1,691</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,014&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization associated with identifiable intangibles</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">15</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Put&#47;call valuation adjustments associated with company's non-consolidating  minority interest investments</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">163</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value creation initiatives</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">24</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$1,893</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,191&#160;</font></td><td style="background-color:#def3c0;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.388%"><tr><td style="width:1.0%"></td><td style="width:68.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diluted earnings per share (EPS)  </font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1Q25 (a)</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1Q24 (a)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$10.30</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$6.11&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization associated with identifiable intangibles</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.12</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.13&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Put&#47;call valuation adjustments associated with company's non-consolidating  minority interest investments</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.35</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.08&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value creation initiatives</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.20</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.24&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.01&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative net tax impact</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(0.39)</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.34)</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$11.58</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$7.23&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Refer to the &#34;Footnotes&#34; section included herein for further explanation of disclosures for Adjusted (non-GAAP) </font></div><div style="padding-left:94.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">financial measures, as well as additional reconciliations.</font></div><div style="margin-top:7pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Please refer to the tables above, as well as the consolidated and segment highlight sections in the detailed earnings release for additional discussion of the factors impacting the year-over-comparisons.</font></div><div style="margin-top:7pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;Our team has done a great job launching us on a strong start to the year. Medicare Advantage is performing as expected and we are excited about our progress in expanding CenterWell and Medicaid,&#8221; said Humana President and CEO Jim Rechtin. &#8220;We are confident in the growth outlook for value-based care and Medicare Advantage, which will allow us to provide more quality care to a broader group of patients and members.</font><font style="color:#212121;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#34;</font></div><div id="id6e7316dbb9e4417b1dec829e92b6aeb_4"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">FY 2025 Earnings Guidance</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Humana revises its GAAP EPS guidance for the year ending December 31, 2025 (FY 2025) to 'approximately $14.68' from 'approximately $15.88', while affirming its Adjusted EPS guidance of 'approximately $16.25'. </font></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.833%"><tr><td style="width:1.0%"></td><td style="width:67.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.408%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"><br></font><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Diluted earnings per share</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FY 2025<br>&#160;Guidance</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FY 2024 (a)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP </font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">approximately <br>$14.68</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9.98&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization associated with identifiable intangibles</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.49</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Put&#47;call valuation adjustments associated with the company's non-consolidating minority interest investments (b)</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.35</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value creation initiatives (b)</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.20</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.33&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.19&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative net tax impact</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.47)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.89)</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP) &#8211; FY 2025 projected (b)&#59; FY 2024 reported</font></td><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">approximately <br>$16.25</font></td><td colspan="2" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$16.21&#160;</font></td><td style="background-color:#def3c0;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Refer to the &#34;Footnotes&#34; section included herein for further explanation of disclosures for Adjusted (non-GAAP) financial measures, as well as additional reconciliations.</font></div><div style="padding-left:18pt;text-indent:-9pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div></div></div><div id="id6e7316dbb9e4417b1dec829e92b6aeb_7"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Detailed Press Release</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Humana&#8217;s full earnings press release, including the statistical pages, has been posted to the company&#8217;s Investor Relations site and may be accessed at https&#58;&#47;&#47;humana.gcs-web.com&#47; or via a current report on Form 8-K filed by the company with the Securities and Exchange Commission this morning (available at www.sec.gov or on the company&#8217;s website).</font></div><div id="id6e7316dbb9e4417b1dec829e92b6aeb_10"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Conference Call</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Humana will host a live question-and-answer session for analysts at 8&#58;00 a.m. Eastern time today to discuss its financial results for the quarter and the company&#8217;s expectations for future earnings. In advance of the question-and-answer session, Humana will post prepared management remarks to the Quarterly Results section of its Investor Relations page (https&#58;&#47;&#47;humana.gcs-web.com&#47;financial-information&#47;quarterly-results).</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">A webcast of the 1Q25 earnings call may be accessed via Humana&#8217;s Investor Relations page at https&#58;&#47;&#47;humana.gcs-web.com&#47;.&#160;</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If you anticipate asking a question during the question-and-answer session, please register in advance at this link - https&#58;&#47;&#47;register-conf.media-server.com&#47;register&#47;BI037cbce4506a41c296e366c2be45b6f2.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique registrant ID.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The company suggests participants listening via the web or the conference call sign in or dial in at least 15 minutes in advance of the call. For those unable to participate in the live event, the virtual presentation archive will be available in the Historical Webcasts and Presentations section of the Investor Relations page at https&#58;&#47;&#47;humana.gcs-web.com&#47;, approximately two hours following the live webcast.  </font></div><div id="id6e7316dbb9e4417b1dec829e92b6aeb_13"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Footnotes</font></div><div style="margin-top:7pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has included financial measures throughout this earnings release that are not in accordance with GAAP. Management believes that these measures, when presented in conjunction with the corresponding GAAP measures, provide a comprehensive perspective to more accurately compare and analyze the company&#8217;s core operating performance over time. Consequently, management uses these non-GAAP (Adjusted) financial measures as consistent and uniform indicators of the company&#8217;s core business operations from period to period, as well as for planning and decision-making purposes and in determination of incentive compensation. Non-GAAP (Adjusted) financial measures should be considered in addition to, but not as a substitute for, or superior to, financial measures prepared in accordance with GAAP. All financial measures in this earnings release are in accordance with GAAP unless otherwise indicated. Please refer to the footnotes for a detailed description of each item adjusted out of GAAP financial measures to arrive at non-GAAP (Adjusted) financial measures.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) For the periods covered in this earnings release, the following items are excluded from the non-GAAP financial measures described above, as applicable.  Note each of the adjustments described below impacted FY 2024 Adjusted EPS as shown on page 2.  </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.02pt">Amortization associated with identifiable intangibles -</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Since amortization varies based on the size and timing of acquisition activity, management believes this exclusion provides a more consistent and uniform indicator of performance from period to period. For all periods shown within this earnings release, </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP measures affected include consolidated pretax results, EPS, and Insurance and CenterWell segments' income from operations. The table below discloses respective period amortization expense for each segment&#58;</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.416%"><tr><td style="width:1.0%"></td><td style="width:49.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amortization </font></div><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</font></div></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q25</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q24</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance segment</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$4</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CenterWell segment</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$11</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$12</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.02pt">Put&#47;call valuation adjustments </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">associated with the company&#8217;s non-consolidating minority interest investments - </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These amounts are the result of fair value measurements associated with the company's primary care strategic partnership and are unrelated to the company's core business operations.</font><font style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all periods shown within this earnings release, GAAP measures affected include consolidated pretax results and </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EPS</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.02pt">Value creation initiatives - </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These charges relate to the company's ongoing initiative to drive additional value for the enterprise through cost saving, productivity initiatives, and value creation from previous investments, and primarily consist of asset impairment, severance charges, and external consulting spend specific to these initiatives. These charges were recorded at the corporate level and not allocated to the segments. For all periods shown within this earnings release, GAAP measures affected in this release include consolidated pretax results, </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EPS</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and the consolidated operating cost ratio.</font><font style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:13.02pt">I</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">mpact of exit of employer group commercial medical products business - </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These amounts relate to activity from the exit of the employer group commercial medical products business as announced by Humana on February 23, 2023.  For 1Q24, GAAP measures affected in this earnings release include consolidated pretax results, </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EPS</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, consolidated revenues, consolidated operating cost ratio, Insurance segment revenues, Insurance segment benefit ratio, Insurance segment operating cost ratio, and Insurance segment income from operations.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.02pt">Impairment charges</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The company recognized non-cash impairment charges in 2024 related to certain indefinite-lived intangible assets based on the company's estimate of future financial performance in certain state markets. These charges were recorded at the corporate level and not allocated to the segments. No impact to 1Q25 or 1Q24 results.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.02pt">Cumulative net tax impact - </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This adjustment represents the cumulative net impact of the corresponding tax benefit or expense related to the aforementioned items excluded from the applicable GAAP measures.  For all periods presented in this earnings release, </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EPS</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the sole GAAP measure affected. </font></div><div style="margin-top:3pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the reconciliations shown on</font><font style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">page 2</font><font style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of this release, the following are reconciliations of GAAP to Adjusted (non-GAAP) measures described above and disclosed within this earnings release&#58;</font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt;text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Revenues</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.361%"><tr><td style="width:1.0%"></td><td style="width:60.896%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.901%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.903%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONSOLIDATED<br>Revenues<br>(in millions)</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q25</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q24</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$32,112</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$29,611</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(279)</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$32,112</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$29,332</font></td></tr></table></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.944%"><tr><td style="width:1.0%"></td><td style="width:60.676%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INSURANCE SEGMENT<br>Revenues <br>(in millions)</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q25</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q24</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$30,937</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$28,699</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(279)</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$30,937</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$28,420</font></td></tr></table></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Insurance Segment Benefit Ratio </font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.805%"><tr><td style="width:1.0%"></td><td style="width:61.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.663%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INSURANCE SEGMENT<br>Benefit ratio</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q25</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q24</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.3&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.4&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Operating Cost Ratio </font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.083%"><tr><td style="width:1.0%"></td><td style="width:61.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.783%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONSOLIDATED<br>Operating cost ratio </font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q25</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q24</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value creation initiatives</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.1)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</font></td><td style="background-color:#def3c0;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.361%"><tr><td style="width:1.0%"></td><td style="width:60.896%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.901%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.903%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INSURANCE SEGMENT<br>Operating cost ratio</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q25</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q24</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><font><br></font></div><div style="text-indent:4.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline">Insurance Segment - Income from Operations</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.222%"><tr><td style="width:1.0%"></td><td style="width:60.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.939%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INSURANCE SEGMENT<br>Income from operations <br>(in millions)</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q25</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q24</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$1,574</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$898</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization associated with identifiable intangibles</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$1,578</font></td><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$903</font></td></tr></table></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b) FY 2025 projected Adjusted results exclude the future impact of items that cannot be estimated at this time.</font></div><div id="id6e7316dbb9e4417b1dec829e92b6aeb_16"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Cautionary Statement</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This news release includes forward-looking statements regarding Humana within the meaning of the Private Securities Litigation Reform Act of 1995. When used in investor presentations, press releases, Securities and Exchange Commission (SEC) filings, and in oral statements made by or with the approval of one of Humana&#8217;s executive officers, the words or phrases like &#8220;expects,&#8221; &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;assumes,&#8221; &#8220;intends,&#8221; &#8220;likely will result,&#8221; &#8220;estimates,&#8221; &#8220;projects&#8221; or variations of such words and similar expressions are intended to identify such forward-looking statements.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions, including, among other things, information set forth in the &#8220;Risk Factors&#8221; section of the company&#8217;s SEC filings, a summary of which includes but is not limited to the following&#58;  </font></div><div style="margin-bottom:2.4pt;padding-left:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">If Humana does not design and price its products properly and competitively, if the premiums Humana receives are insufficient to cover the cost of healthcare services delivered to its members, if the company is unable to implement clinical initiatives to provide a better healthcare experience for its members, lower costs and appropriately document the risk profile of its members, or if its estimates of benefits expense are inadequate, Humana&#8217;s profitability could be materially adversely affected. Humana estimates the costs of its benefit expense payments, and designs and prices its products accordingly, using actuarial methods and assumptions based upon, among other relevant factors, claim payment patterns, medical cost inflation, and historical developments such as claim inventory levels and claim receipt patterns. The company continually reviews estimates of future payments relating to benefit </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">expenses for services incurred in the current and prior periods and makes necessary adjustments to its reserves, including premium deficiency reserves, where appropriate. These estimates involve extensive judgment, and have considerable inherent variability because they are extremely sensitive to changes in claim payment patterns and medical cost trends. Accordingly, Humana's reserves may be insufficient.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">If Humana fails to effectively implement its operational and strategic initiatives, including its Medicare initiatives, which are of particular importance given the concentration of the company's revenues in these products, state-based contract strategy, the growth of its CenterWell business, and its integrated care delivery model, the company&#8217;s business may be materially adversely affected.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">The number of Humana&#8217;s Medicare Advantage plans rated 4-star or higher will significantly decline in 2025.  Humana has filed a lawsuit seeking to set aside and vacate the 2025 Star Ratings of its Medicare Advantage plans, but there is no assurance that the company will prevail in this lawsuit. If the company is not successful, the decline in Star Ratings will negatively impact its 2026 quality bonus payments from CMS and may also significantly adversely affect the company&#8217;s revenues, operating results, and cash flows. In addition, there can be no assurances the company will be successful in maintaining or improving its Star Ratings in future years. </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">If Humana, or the third-party service providers on which it relies, fails to properly maintain the integrity of its data, to strategically maintain existing or implement new information systems, to protect Humana&#8217;s proprietary rights to its systems, or to defend against cyber-security attacks, contain such attacks when they occur, or prevent other privacy or data security incidents that result in security breaches that disrupt the company's operations or in the unintentional dissemination of sensitive personal information or proprietary or confidential information, the company&#8217;s business may be materially adversely affected.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Humana is involved in various legal actions, or disputes that could lead to legal actions (such as, among other things, provider contract disputes and qui tam litigation brought by individuals on behalf of the government), governmental and internal investigations, and routine internal review of business processes any of which, if resolved unfavorably to the company, could result in substantial monetary damages or changes in its business practices. Increased litigation and negative publicity could also increase the company&#8217;s cost of doing business.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">As a government contractor, Humana is exposed to risks that may materially adversely affect its business or its willingness or ability to participate in government healthcare programs including, among other things, loss of material government contracts&#59; governmental audits and investigations&#59; potential inadequacy of government determined payment rates&#59; potential restrictions on profitability, including by comparison of profitability of the company&#8217;s Medicare Advantage business to non-Medicare Advantage business&#59; or other changes in the governmental programs in which Humana participates. Changes to the risk-adjustment model utilized by CMS to adjust premiums paid to Medicare Advantage plans or retrospective recovery by CMS of previously paid premiums as a result of the final rule related to the risk adjustment data validation audit methodology published by CMS on January 30, 2023 (Final RADV Rule), which Humana believes fails to address adequately the statutory requirement of actuarial equivalence and violates the Administrative Procedure Act due to its failure to include a &#34;Fee for Service Adjuster&#34; could have a material adverse effect on the company's operating results, financial position and cash flows. </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Humana's business activities are subject to substantial government regulation.  New laws or regulations, or legislative, judicial, or regulatory changes in existing laws or regulations or their manner of application could increase the company's cost of doing business and have a material adverse effect on Humana&#8217;s results of operations (including restricting revenue, enrollment and premium growth in certain products and market segments, restricting the company&#8217;s ability to expand into new markets, increasing the company&#8217;s medical and operating costs by, among other things, requiring a minimum benefit ratio on insured products, lowering the company&#8217;s Medicare payment rates and increasing the company&#8217;s expenses associated with a non-deductible health insurance industry fee and other assessments)&#59; the company&#8217;s financial position (including the company&#8217;s ability to maintain the value of its goodwill)&#59; and the company&#8217;s cash flows.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Humana&#8217;s failure to manage acquisitions, divestitures and other significant transactions successfully may have a material adverse effect on the company&#8217;s results of operations, financial position, and cash flows. </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">If Humana fails to develop and maintain satisfactory relationships with the providers of care to its members, the company&#8217;s business may be adversely affected.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">Humana faces significant competition in attracting and retaining talented employees. Further, managing succession for, and retention of, key executives is critical to the Company&#8217;s success, and its failure to do so could adversely affect the Company&#8217;s businesses, operating results and&#47;or future performance.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Humana&#8217;s pharmacy business is highly competitive and subjects it to regulations and supply chain risks in addition to those the company faces with its core health benefits businesses.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Changes in the prescription drug industry pricing benchmarks may adversely affect Humana&#8217;s financial performance.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Humana&#8217;s ability to obtain funds from certain of its licensed subsidiaries is restricted by state insurance regulations.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Downgrades in Humana&#8217;s debt ratings, should they occur, may adversely affect its business, results of operations, and financial condition.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Volatility or disruption in the securities and credit markets may significantly and adversely affect the value of our investment portfolio and the investment income that we derive from this portfolio.    </font></div><div style="padding-left:36pt;text-align:justify;text-indent:4.5pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In making forward-looking statements, Humana is not undertaking to address or update them in future filings or communications regarding its business or results. In light of these risks, uncertainties, and assumptions, the forward-looking events discussed herein may or may not occur. There also may be other risks that the company is unable to predict at this time. Any of these risks and uncertainties may cause actual results to differ materially from the results discussed in the forward-looking statements.  </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Humana advises investors to read the following documents as filed by the company with the SEC for further discussion both of the risks it faces and its historical performance&#58; </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Form 10-K for the year ended December&#160;31, 2024&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Form 8-Ks filed during 2025. </font></div><div><font><br></font></div><div id="id6e7316dbb9e4417b1dec829e92b6aeb_19"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">About Humana </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Humana Inc. is committed to putting health first &#8211; for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health &#8211; delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.  </font></div><div style="margin-top:12pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>hum-2025q18kxex99x2detailed.htm
<DESCRIPTION>EX-99.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i900a727b98754728b9e3a3880bb98a4e_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:22.083%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">n e w s  r e l e a s e</font></td><td colspan="3" style="display:none"></td></tr></table><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:1pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.555%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 99.2</font></div></td></tr></table></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:125.25pt"><tr><td style="width:1.0pt"></td><td style="width:123.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:60pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Humana Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">500 West Main Street</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">P.O. Box 1438</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Louisville, KY 40202</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">http&#58;&#47;&#47;www.humana.com</font></div></td></tr></table></div><div style="margin-top:7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">FOR MORE INFORMATION CONTACT&#58;</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.817%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Lisa Stoner<br>Humana Investor Relations<br>(502) 580-2652<br>e-mail&#58; LStamper&#64;humana.com</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><img alt="humanalogoa051.jpg" src="humanalogoa051.jpg" style="height:65px;margin-bottom:5pt;vertical-align:text-bottom;width:217px"></div></td></tr></table></div><div style="margin-top:7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Mark Taylor</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Humana Corporate Communications</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(317) 753-0345</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">e-mail&#58; MTaylor108&#64;humana.com</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#5c9a1b;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Humana Reports First Quarter 2025 Financial Results&#59; </font></div><div style="text-align:center"><font style="color:#5c9a1b;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Affirms Full Year 2025 Adjusted Financial Guidance </font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Reports 1Q25 earnings per share (EPS) of $10.30 on a GAAP basis, Adjusted EPS of $11.58</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">1Q25 Insurance segment benefit ratio of 87.4 percent, in line with the company's previously disclosed expectation of 'approximately 87.5 percent'</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Affirms Adjusted FY 2025 EPS guidance of 'approximately $16.25'&#59; while revising GAAP EPS to 'approximately $14.68' from the previous estimate of 'approximately $15.88'</font><font style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Affirms FY 2025 Insurance segment benefit ratio guidance range of 90.1 percent to 90.5 percent</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Affirms expected individual Medicare Advantage annual membership decline of approximately 550,000, inclusive of the impact of exiting certain unprofitable plans and counties</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">Remains confident in 2025 pricing strategy as the company prioritizes membership that is expected to drive sustainable, long-term value creation</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.02pt">Continues to advance the company's long-term strategy with achievements within the CenterWell and Medicaid businesses</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.59pt">CenterWell Pharmacy selected as the fulfillment pharmacy for NovoCare</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#174;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Pharmacy&#8217;s weight loss medication for cash pay customers</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.59pt">Illinois announced its intent to award the company a contract for the state's new Fully Integrated Dual Eligible Special Needs Plan program </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Publishes prepared management remarks to Investor Relations page of www.humana.com ahead of this morning's 8&#58;00 a.m. ET question and answer session to discuss its financial results for the quarter and expectations for future earnings</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">LOUISVILLE, KY (April 30, 2025)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> &#8211; Humana Inc. (NYSE&#58; HUM) today reported consolidated pretax results and net  earnings per share (EPS) for the quarter ended March 31, 2025 (1Q25) versus the quarter ended March 31, 2024 (1Q24) as noted in the tables below.</font></div><div style="text-align:center"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.666%"><tr><td style="width:1.0%"></td><td style="width:68.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.117%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.299%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated income before income taxes and equity in net losses (pretax results) </font></div><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">in millions</font></div></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1Q25 (a)</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1Q24 (a)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Generally Accepted Accounting Principles (GAAP)</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$1,691</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,014&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization associated with identifiable intangibles</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">15</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Put&#47;call valuation adjustments associated with company's non-consolidating  minority interest investments</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">163</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value creation initiatives</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">24</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$1,893</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,191&#160;</font></td><td style="background-color:#def3c0;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.388%"><tr><td style="width:1.0%"></td><td style="width:68.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diluted earnings per share (EPS)  </font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1Q25 (a)</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1Q24 (a)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$10.30</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$6.11&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization associated with identifiable intangibles</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.12</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.13&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Put&#47;call valuation adjustments associated with company's non-consolidating  minority interest investments</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.35</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.08&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value creation initiatives</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.20</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.24&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.01&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative net tax impact</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(0.39)</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.34)</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$11.58</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$7.23&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:94.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Refer to the &#34;Footnotes&#34; section included herein for further explanation of disclosures for Adjusted (non-GAAP) </font></div><div style="padding-left:94.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">financial measures, as well as additional reconciliations.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Please refer to the tables above, as well as the consolidated and segment highlight sections that follow for additional discussion of the factors impacting the year-over-year comparisons. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;Our team has done a great job launching us on a strong start to the year. Medicare Advantage is performing as expected and we are excited about our progress in expanding CenterWell and Medicaid,&#8221; said Humana President and CEO Jim Rechtin. &#8220;We are confident in the growth outlook for value-based care and Medicare Advantage, which will allow us to provide more quality care to a broader group of patients and members.</font><font style="color:#212121;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#34;</font></div><div id="i900a727b98754728b9e3a3880bb98a4e_7"></div><div><font><br></font></div><div id="i900a727b98754728b9e3a3880bb98a4e_13"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">FY 2025 Earnings Guidance</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Humana revises its GAAP EPS guidance for the year ending December 31, 2025 (FY 2025) to 'approximately $14.68' from 'approximately $15.88', while affirming its Adjusted EPS guidance of 'approximately $16.25'. Additional FY 2025 guidance points are included on page 12 of this earnings release.</font></div><div style="margin-top:6pt;padding-right:-11.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.944%"><tr><td style="width:1.0%"></td><td style="width:65.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"><br></font><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Diluted earnings per share</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FY 2025<br>&#160;Guidance</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FY 2024 (a)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP </font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">approximately <br>$14.68</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9.98&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization associated with identifiable intangibles</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.49</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Put&#47;call valuation adjustments associated with the company's non-consolidating minority interest investments (b)</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.35</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value creation initiatives (b)</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.20</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.33&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.19&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative net tax impact</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.47)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.89)</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP) &#8211; FY 2025 projected (b)&#59; FY 2024 reported</font></td><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">approximately <br>$16.25</font></td><td colspan="2" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$16.21&#160;</font></td><td style="background-color:#def3c0;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:107%">Refer to the &#34;Footnotes&#34; section included herein for further explanation of disclosures for Adjusted (non-GAAP) financial measures, as well</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:107%">as additional reconciliations.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div></div></div><div id="i900a727b98754728b9e3a3880bb98a4e_19"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Humana Consolidated Highlights</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.361%"><tr><td style="width:1.0%"></td><td style="width:60.896%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.901%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.903%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Humana Inc. Summary of Results<br></font><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions, except per share amounts)</font></div></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1Q25 (a)</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1Q24 (a)</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues </font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$32,112</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$29,611</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues - Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$32,112</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$29,332</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax results</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$1,691</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,014</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax results - Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$1,893</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,191</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$10.30</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.11</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS - Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$11.58</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7.23</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit ratio</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87.0</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.9&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cost ratio</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cost ratio - Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows </font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$331</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$423</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parent company cash and short term investments</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$1,234</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$509</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt-to-total capitalization</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42.8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.1&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Days in Claims Payable (DCP)</font></td><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.8</font></td><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.5</font></td></tr></table></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Refer to the &#34;Footnotes&#34; section included herein for further explanation of disclosures for Adjusted (non-GAAP)</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">financial measures, as well as reconciliations.</font></div><div id="i900a727b98754728b9e3a3880bb98a4e_25"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Consolidated Revenues</font></div><div style="margin-top:7pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">favorable</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> year-over-year GAAP consolidated revenues comparison was primarily driven by the following factors&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">higher per member</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Medicare and state-based contracts premiums&#59; the Medicare increase was driven largely by an increased direct subsidy due to the Inflation Reduction Act (IRA), and </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">membership growth in the company's stand-alone PDP and state-based contracts businesses. </font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">These factors were partially offset by the membership decline within the individual Medicare Advantage business, inclusive of the company's decision to exit certain unprofitable plans and counties.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Refer to the &#34;Footnotes&#34; section included herein for a reconciliation of GAAP to Adjusted (non-GAAP) consolidated revenues for the respective periods. </font></div><div id="i900a727b98754728b9e3a3880bb98a4e_31"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Consolidated Benefit Ratio</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The year-over-year decline in the GAAP consolidated benefit ratio primarily reflected the following items&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.02pt">individual Medicare Advantage pricing inclusive of plan exits, benefit design changes, and favorable workday impacts in 1Q25 more than offsetting claims trend and the funding environment, and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">the change in Medicare Part D seasonality due to the IRA. </font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">These factors were partially offset by t</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">he following&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">a shift in line of business mix resulting from reductions in individual Medicare Advantage membership</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, combined with growth in the stand-alone PDP and state-based contracts businesses, which carry a higher benefit ratio, </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">delayed flu season that led to a more acute period in 1Q25 compared to 1Q24, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">and</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">lower favorable prior period medical claims reserve development.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Refer to the &#34;Footnotes&#34; section included herein for a reconciliation of GAAP to Adjusted (non-GAAP) consolidated benefit ratios for the respective periods. </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;text-decoration:underline">Prior Period Medical Claims Reserve Development (Prior Period Development)</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.972%"><tr><td style="width:1.0%"></td><td style="width:27.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="background-color:#5c9a1b;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Consolidated Favorable Prior Period Development</font></div><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">$ in millions</font></div><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Basis points (bps)</font></div></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">First<br>Quarter</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Prior Period Development from prior years recognized in 2025</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$477</font></td></tr><tr><td colspan="9" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Decrease to GAAP benefit ratio</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(160 bps)</font></td></tr><tr><td colspan="9" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Prior Period Development from prior years recognized in 2024 </font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$535</font></td></tr><tr><td colspan="9" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Decrease to GAAP benefit ratio</font></td><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(190 bps)</font></td></tr></table></div><div id="i900a727b98754728b9e3a3880bb98a4e_37"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Consolidated Operating Cost Ratio</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The year-over-year increase in the GAAP consolidated operating cost ratio from 1Q24 primarily resulted from business mix changes, including within the CenterWell segment which runs a significantly higher operating cost ratio than the Insurance segment, combined with the operating leverage impact of the loss of individual Medicare Advantage membership.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This was partially offset by the following items&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">administrative cost efficiencies resulting from the company's value creation initiatives, and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">operating leverage associated with </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">increased revenues from the impact of the IRA as described above.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Refer to the &#34;Footnotes&#34; section included herein for a reconciliation of GAAP to Adjusted (non-GAAP) consolidated operating cost ratios for the respective periods. </font></div><div id="i900a727b98754728b9e3a3880bb98a4e_43"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Balance sheet</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Days in claims payable (DCP) of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">38.8</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> days at March 31, 2025 represented an in</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">crease</font><font style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of 1.0 day</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">from 37.8 days at </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">December 31, 2024</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and a decrease of 3.7</font><font style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">days from 42.5 days at March 31, 2024. </font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The 1.0 day sequential increase was primarily driven by increased processed claims inventory as of March 31, 2025 compared to December 31, 2024.  </font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The 3.7</font><font style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">days year-over-year decrease was primarily driven by an increased proportion of Medicare prescription drug benefit expense as a result of structural changes associated with the IRA. Pharmacy claims are processed more quickly than medical claims leading to a lower DCP.</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">Humana's debt-to-total capitalization at March 31</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">, 2025 </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">increased 90 basis points to 42.8 percent fro</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">m 41.9 p</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">ercent at December 31</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">, 2024 </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">primarily driven by the $1.5 billion issuance of senior notes in March 2025, partially offset by the impact of 1Q25 net earnings.</font></div><div id="i900a727b98754728b9e3a3880bb98a4e_49"></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Operating cash flows</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The year-over-year decrease in GAAP operating cash flows primarily reflected the unfavorable impact of working capital items, partially offset by higher earnings in 1Q25.</font></div><div id="i900a727b98754728b9e3a3880bb98a4e_64"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Humana&#8217;s Insurance Segment</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This segment is comprised of insurance products serving Medicare and state-based contract beneficiaries, as well as individuals and employers. The segment also includes the company's Pharmacy Benefit Manager, or PBM, business.   </font></div><div style="text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.361%"><tr><td style="width:1.0%"></td><td style="width:62.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.327%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Insurance Segment Results<br></font><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</font></div></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q25 (a)</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q24 (a)</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$30,937</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$28,699</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues - Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$30,937</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$28,420</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit ratio</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.3&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit ratio - Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.4&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cost ratio</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cost ratio - Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$1,574</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$898</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations - Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$1,578</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$903</font></td></tr></table></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Refer to the &#34;Footnotes&#34; section included herein for further explanation of disclosures for Adjusted </font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(non-GAAP) financial measures, as well as recalculations.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Insurance Segment Revenues</font></div><div style="margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The year-over-year </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">increase</font><font style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in GAAP segment revenues from 1Q24 primarily reflected the following items&#58; </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">higher per member</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Medicare and state-based contracts premiums&#59; the Medicare increase was driven largely by an increased direct subsidy due to the IRA, and </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">membership growth in the company's stand-alone PDP and state-based contracts businesses. </font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">These factors were partially offset by the membership decline within the individual Medicare Advantage business, inclusive of the company's decision to exit certain unprofitable plan and counties.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Refer to the &#34;Footnotes&#34; section included herein for a reconciliation of GAAP to Adjusted (non-GAAP) Insurance segment revenues for the respective periods. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Insurance Segment Benefit Ratio</font></div><div style="margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The year-over-year </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">decline </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">in the GAAP segment benefit ratio primarily reflected the following items&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.02pt">individual Medicare Advantage pricing inclusive of plan exits, benefit design changes, and favorable workday impacts in 1Q25 more than offsetting claims trend and the funding environment, and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">the change in Medicare Part D seasonality due to the IRA. </font></div><div style="margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">These factors were partially offset by t</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">he following&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">a shift in line of business mix resulting from reductions in individual Medicare Advantage membership</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, combined with growth in the stand-alone PDP and state-based contracts businesses, which carry a higher benefit ratio, </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">delayed flu season which led to a more acute period in 1Q25 compared to 1Q24, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">lower favorable prior period medical claims reserve development.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Refer to the &#34;Footnotes&#34; section included herein for a reconciliation of GAAP to Adjusted (non-GAAP) Insurance segment benefit ratios for the respective periods.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%"> </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">Insurance Segment Operating Cost Ratio</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The year-over-year decrease in the GAAP segment operating cost ratio from 1Q24 primarily related to the following&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">administrative cost efficiencies resulting from the company's value creation initiatives, and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">operating leverage associated with increased revenues from the impact of the IRA as described above.  </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">These factors were partially offset by the operating leverage impact of the loss of individual Medicare Advantage membership.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Refer to the &#34;Footnotes&#34; section included herein for a reconciliation of GAAP to Adjusted (non-GAAP) Insurance segment operating cost ratios for the respective periods. </font></div><div id="i900a727b98754728b9e3a3880bb98a4e_76"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Humana&#8217;s CenterWell Segment</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This segment includes pharmacy (excluding the PBM operations), primary care, and home solutions. Services offered by this segment are designed to enhance the overall healthcare experience. These services may lead to lower utilization associated with improved member health and&#47;or lower drug costs.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.361%"><tr><td style="width:1.0%"></td><td style="width:60.896%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.901%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.903%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CenterWell Segment Results<br></font><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</font></div></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q25</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q24</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$5,095</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,818</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cost ratio</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">91.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.0&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$392</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$282</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations - Adjusted (non-GAAP) (c)</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$451</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$335</font></td></tr></table></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Refer to the &#34;Footnotes&#34; section included herein for further explanation of disclosures for Adjusted (non-GAAP) </font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">financial measures, as well as reconciliations.  </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">CenterWell Segment Revenues</font></div><div style="margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The favorable year-over-year CenterWell segment revenues comparison was primarily driven by </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">higher revenues associated with growth in the company's primary care business, partially offset by the impact of the v28 risk model revision.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">CenterWell Segment Operating Cost Ratio</font></div><div style="margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The year-over-year</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> decrease i</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">n the segment's operating cost ratio primarily resulted from the following&#58;</font></div><div style="margin-top:12pt;padding-left:49.5pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">administrative cost efficiencies resulting from the company's value creation initiatives, and</font></div><div style="margin-top:12pt;padding-left:49.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">more favorable operating trends in the primary care business in 1Q25 as a result of stabilizing medical cost trends and maturation of the company's v28 mitigation activities, partially offset by the continued phase-in of v28. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">See additional operational metrics for the CenterWell segment on pages S-11 through S-13 of the statistical supplement included in this earnings release.</font></div><div id="i900a727b98754728b9e3a3880bb98a4e_82"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Conference Call</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Humana will host a live question-and-answer session for analysts at 8&#58;00 a.m. Eastern time today to discuss its financial results for the quarter and the company&#8217;s expectations for future earnings. In advance of the question-and-answer </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">session, Humana will post prepared management remarks to the Quarterly Results section of its Investor Relations page (https&#58;&#47;&#47;humana.gcs-web.com&#47;financial-information&#47;quarterly-results).</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">A webcast of the 1Q25 earnings call may be accessed via Humana&#8217;s Investor Relations page at https&#58;&#47;&#47;humana.gcs-web.com&#47;.&#160;</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If you anticipate asking a question during the question-and-answer session, please register in advance at this link - https&#58;&#47;&#47;register-conf.media-server.com&#47;register&#47;BI037cbce4506a41c296e366c2be45b6f2.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique registrant ID.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The company suggests participants listening via the web or the conference call sign in or dial in at least 15 minutes in advance of the call. For those unable to participate in the live event, the virtual presentation archive will be available in the Historical Webcasts and Presentations section of the Investor Relations page at https&#58;&#47;&#47;humana.gcs-web.com&#47;, approximately two hours following the live webcast.  </font></div><div id="i900a727b98754728b9e3a3880bb98a4e_85"></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Footnotes</font></div><div style="margin-top:7pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has included financial measures throughout this earnings release that are not in accordance with GAAP. Management believes that these measures, when presented in conjunction with the corresponding GAAP measures, provide a comprehensive perspective to more accurately compare and analyze the company&#8217;s core operating performance over time. Consequently, management uses these non-GAAP (Adjusted) financial measures as consistent and uniform indicators of the company&#8217;s core business operations from period to period, as well as for planning and decision-making purposes and in determination of incentive compensation. Non-GAAP (Adjusted) financial measures should be considered in addition to, but not as a substitute for, or superior to, financial measures prepared in accordance with GAAP. All financial measures in this earnings release are in accordance with GAAP unless otherwise indicated. Please refer to the footnotes for a detailed description of each item adjusted out of GAAP financial measures to arrive at non-GAAP (Adjusted) financial measures.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) For the periods covered in this earnings release, the following items are excluded from the non-GAAP financial measures described above, as applicable.  Note each of the adjustments described below impacted FY 2024 Adjusted EPS as shown on page 2.  </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.02pt">Amortization associated with identifiable intangibles -</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Since amortization varies based on the size and timing of acquisition activity, management believes this exclusion provides a more consistent and uniform indicator of performance from period to period. For all periods shown within this earnings release, </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP measures affected include consolidated pretax results, EPS, and Insurance and CenterWell segments' income from operations. The table below discloses respective period amortization expense for each segment&#58;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.416%"><tr><td style="width:1.0%"></td><td style="width:49.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amortization </font></div><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</font></div></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q25</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q24</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance segment</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$4</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CenterWell segment</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$11</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$12</font></td></tr></table></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.02pt">Put&#47;call valuation adjustments </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">associated with the company&#8217;s non-consolidating minority interest investments - </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These amounts are the result of fair value measurements associated with the company's primary care strategic partnership and are unrelated to the company's core business operations.</font><font style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all periods shown within this earnings release, GAAP measures affected include consolidated pretax results and </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EPS</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.02pt">Value creation initiatives - </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These charges relate to the company's ongoing initiative to drive additional value for the enterprise through cost saving, productivity initiatives, and value creation from previous investments, and primarily consist of asset impairment, severance charges, and external consulting spend specific to these initiatives. These charges were recorded at the corporate level and not allocated to the segments. For all periods shown within this earnings release, GAAP measures affected in this release include consolidated pretax results, </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EPS</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and the consolidated operating cost ratio.</font><font style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:13.02pt">I</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">mpact of exit of employer group commercial medical products business - </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These amounts relate to activity from the exit of the employer group commercial medical products business as announced by Humana on February 23, 2023.  For 1Q24, GAAP measures affected in this earnings release include consolidated pretax results, </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EPS</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, consolidated revenues, </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated operating cost ratio, Insurance segment revenues, Insurance segment benefit ratio, Insurance segment operating cost ratio, and Insurance segment income from operations.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.02pt">Impairment charges</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The company recognized non-cash impairment charges in 2024 related to certain indefinite-lived intangible assets based on the company's estimate of future financial performance in certain state markets. These charges were recorded at the corporate level and not allocated to the segments. No impact to 1Q25 or 1Q24 results.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.02pt">Cumulative net tax impact - </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This adjustment represents the cumulative net impact of the corresponding tax benefit or expense related to the aforementioned items excluded from the applicable GAAP measures.  For all periods presented in this earnings release, </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EPS</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the sole GAAP measure affected.  </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the reconciliations shown on</font><font style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">page 2</font><font style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of this release, the following are reconciliations of GAAP to Adjusted (non-GAAP) measures described above and disclosed within this earnings release&#58;</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Revenues</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.361%"><tr><td style="width:1.0%"></td><td style="width:60.896%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.901%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.903%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONSOLIDATED</font></div><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Revenues</font></div><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</font></div></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q25</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q24</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$32,112</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$29,611</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(279)</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$32,112</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$29,332</font></td></tr></table></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.944%"><tr><td style="width:1.0%"></td><td style="width:60.676%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INSURANCE SEGMENT</font></div><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Revenues </font></div><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</font></div></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q25</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q24</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$30,937</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$28,699</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(279)</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$30,937</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$28,420</font></td></tr></table></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><font><br></font></div><div style="text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Insurance Segment Benefit Ratio </font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.805%"><tr><td style="width:1.0%"></td><td style="width:61.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.663%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INSURANCE SEGMENT<br>Benefit ratio</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q25</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q24</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.3&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.4&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Operating Cost Ratio </font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.083%"><tr><td style="width:1.0%"></td><td style="width:61.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.783%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONSOLIDATED<br>Operating cost ratio </font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q25</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q24</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value creation initiatives</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.1)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</font></td><td style="background-color:#def3c0;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.361%"><tr><td style="width:1.0%"></td><td style="width:60.896%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.901%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.903%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INSURANCE SEGMENT<br>Operating cost ratio</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q25</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q24</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Insurance Segment - Income from Operations</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.222%"><tr><td style="width:1.0%"></td><td style="width:60.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.939%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INSURANCE SEGMENT</font></div><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Income from operations </font></div><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</font></div></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q25</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q24</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$1,574</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$898</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization associated with identifiable intangibles</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$1,578</font></td><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$903</font></td></tr></table></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b) FY 2025 projected Adjusted results exclude the future impact of items that cannot be estimated at this time.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(c) The CenterWell segment Adjusted income from operations includes an adjustment to add back depreciation and amortization expense to the segment's GAAP income from operations since such an adjustment is commonly utilized for valuation purposes within the healthcare delivery industry. </font><font style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">  </font></div><div style="margin-bottom:12pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.222%"><tr><td style="width:1.0%"></td><td style="width:60.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.939%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CENTERWELL SEGMENT </font></div><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Income from operations </font></div><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</font></div></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q25</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q24</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$392</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$282</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">59</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$451</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$335&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div id="i900a727b98754728b9e3a3880bb98a4e_97"></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Cautionary Statement</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This news release includes forward-looking statements regarding Humana within the meaning of the Private Securities Litigation Reform Act of 1995. When used in investor presentations, press releases, Securities and Exchange Commission (SEC) filings, and in oral statements made by or with the approval of one of Humana&#8217;s executive officers, the words or phrases like &#8220;expects,&#8221; &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;assumes,&#8221; &#8220;intends,&#8221; &#8220;likely will result,&#8221; &#8220;estimates,&#8221; &#8220;projects&#8221; or variations of such words and similar expressions are intended to identify such forward-looking statements.  </font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions, including, among other things, information set forth in the &#8220;Risk Factors&#8221; section of the company&#8217;s SEC filings, a summary of which includes but is not limited to the following&#58;  </font></div><div style="margin-bottom:2.4pt;padding-left:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">If Humana does not design and price its products properly and competitively, if the premiums Humana receives are insufficient to cover the cost of healthcare services delivered to its members, if the company is unable to implement clinical initiatives to provide a better healthcare experience for its members, lower costs and appropriately document the risk profile of its members, or if its estimates of benefits expense are inadequate, Humana&#8217;s profitability could be materially adversely affected. Humana estimates the costs of its benefit expense payments, and designs and prices its products accordingly, using actuarial methods and assumptions based upon, among other relevant factors, claim payment patterns, medical cost inflation, and historical developments such as claim inventory levels and claim receipt patterns. The company continually reviews estimates of future payments relating to benefit expenses for services incurred in the current and prior periods and makes necessary adjustments to its </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">reserves, including premium deficiency reserves, where appropriate. These estimates involve extensive judgment, and have considerable inherent variability because they are extremely sensitive to changes in claim payment patterns and medical cost trends. Accordingly, Humana's reserves may be insufficient.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">If Humana fails to effectively implement its operational and strategic initiatives, including its Medicare initiatives, which are of particular importance given the concentration of the company's revenues in these products, state-based contract strategy, the growth of its CenterWell business, and its integrated care delivery model, the company&#8217;s business may be materially adversely affected.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">The number of Humana&#8217;s Medicare Advantage plans rated 4-star or higher will significantly decline in 2025.  Humana has filed a lawsuit seeking to set aside and vacate the 2025 Star Ratings of its Medicare Advantage plans, but there is no assurance that the company will prevail in this lawsuit. If the company is not successful, the decline in Star Ratings will negatively impact its 2026 quality bonus payments from CMS and may also significantly adversely affect the company&#8217;s revenues, operating results, and cash flows. In addition, there can be no assurances the company will be successful in maintaining or improving its Star Ratings in future years. </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">If Humana, or the third-party service providers on which it relies, fails to properly maintain the integrity of its data, to strategically maintain existing or implement new information systems, to protect Humana&#8217;s proprietary rights to its systems, or to defend against cyber-security attacks, contain such attacks when they occur, or prevent other privacy or data security incidents that result in security breaches that disrupt the company's operations or in the unintentional dissemination of sensitive personal information or proprietary or confidential information, the company&#8217;s business may be materially adversely affected.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Humana is involved in various legal actions, or disputes that could lead to legal actions (such as, among other things, provider contract disputes and qui tam litigation brought by individuals on behalf of the government), governmental and internal investigations, and routine internal review of business processes any of which, if resolved unfavorably to the company, could result in substantial monetary damages or changes in its business practices. Increased litigation and negative publicity could also increase the company&#8217;s cost of doing business.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">As a government contractor, Humana is exposed to risks that may materially adversely affect its business or its willingness or ability to participate in government healthcare programs including, among other things, loss of material government contracts&#59; governmental audits and investigations&#59; potential inadequacy of government determined payment rates&#59; potential restrictions on profitability, including by comparison of profitability of the company&#8217;s Medicare Advantage business to non-Medicare Advantage business&#59; or other changes in the governmental programs in which Humana participates. Changes to the risk-adjustment model utilized by CMS to adjust premiums paid to Medicare Advantage plans or retrospective recovery by CMS of previously paid premiums as a result of the final rule related to the risk adjustment data validation audit methodology published by CMS on January 30, 2023 (Final RADV Rule), which Humana believes fails to address adequately the statutory requirement of actuarial equivalence and violates the Administrative Procedure Act due to its failure to include a &#34;Fee for Service Adjuster&#34; could have a material adverse effect on the company's operating results, financial position and cash flows. </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Humana's business activities are subject to substantial government regulation.  New laws or regulations, or legislative, judicial, or regulatory changes in existing laws or regulations or their manner of application could increase the company's cost of doing business and have a material adverse effect on Humana&#8217;s results of operations (including restricting revenue, enrollment and premium growth in certain products and market segments, restricting the company&#8217;s ability to expand into new markets, increasing the company&#8217;s medical and operating costs by, among other things, requiring a minimum benefit ratio on insured products, lowering the company&#8217;s Medicare payment rates and increasing the company&#8217;s expenses associated with a non-deductible health insurance industry fee and other assessments)&#59; the company&#8217;s financial position (including the company&#8217;s ability to maintain the value of its goodwill)&#59; and the company&#8217;s cash flows.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Humana&#8217;s failure to manage acquisitions, divestitures and other significant transactions successfully may have a material adverse effect on the company&#8217;s results of operations, financial position, and cash flows. </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">If Humana fails to develop and maintain satisfactory relationships with the providers of care to its members, the company&#8217;s business may be adversely affected.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">Humana faces significant competition in attracting and retaining talented employees. Further, managing succession for, and retention of, key executives is critical to the Company&#8217;s success, and its failure to do so could adversely affect the Company&#8217;s businesses, operating results and&#47;or future performance.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Humana&#8217;s pharmacy business is highly competitive and subjects it to regulations and supply chain risks in addition to those the company faces with its core health benefits businesses.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Changes in the prescription drug industry pricing benchmarks may adversely affect Humana&#8217;s financial performance.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Humana&#8217;s ability to obtain funds from certain of its licensed subsidiaries is restricted by state insurance regulations.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Downgrades in Humana&#8217;s debt ratings, should they occur, may adversely affect its business, results of operations, and financial condition.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Volatility or disruption in the securities and credit markets may significantly and adversely affect the value of our investment portfolio and the investment income that we derive from this portfolio.    </font></div><div style="padding-left:36pt;text-align:justify;text-indent:4.5pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In making forward-looking statements, Humana is not undertaking to address or update them in future filings or communications regarding its business or results. In light of these risks, uncertainties, and assumptions, the forward-looking events discussed herein may or may not occur. There also may be other risks that the company is unable to predict at this time. Any of these risks and uncertainties may cause actual results to differ materially from the results discussed in the forward-looking statements.  </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Humana advises investors to read the following documents as filed by the company with the SEC for further discussion both of the risks it faces and its historical performance&#58; </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Form 10-K for the year ended December&#160;31, 2024&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Form 8-Ks filed during 2025. </font></div><div id="i900a727b98754728b9e3a3880bb98a4e_100"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">About Humana </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Humana Inc. is committed to putting health first &#8211; for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health &#8211; delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.  </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.833%"><tr><td style="width:1.0%"></td><td style="width:26.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:35.750%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:34.528%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%;text-decoration:underline">Humana Inc. Full Year 2025 Projections - As of April 30, 2025</font></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">no changes from initial guidance provided as of February 11, 2025, with the exception of GAAP EPS </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Diluted earnings per common share (EPS)</font></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GAAP&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">approximately $14.68</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(previously approximately $15.88)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Non-GAAP&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> approximately $16.25</font></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Total Revenues</font></td></tr><tr style="height:39pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Consolidated</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GAAP&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> $126 billion to $128 billion</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated and segment level revenue projections include expected investment income.<br>Segment level revenues include amounts that eliminate in consolidation.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Insurance segment</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GAAP&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$121 billion to $123 billion</font></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CenterWell segment</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GAAP&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$20.5 billion to $21.5 billion</font></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Change in year-end medical membership from prior year-end</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Individual Medicare Advantage</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Decline of approximately 550,000</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Group Medicare Advantage</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Relatively flat</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Growth of approximately 200,000</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">State-based contracts</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Growth within 175,000 to 250,000 range</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State-based contracts guidance includes membership in Florida, Illinois, Indiana, Kentucky, Louisiana, Ohio, Oklahoma, South Carolina, Virginia, and Wisconsin.</font></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Benefit Ratio</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;Insurance segment</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GAAP&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> 90.1% to 90.5%</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ratio calculation&#58; benefits expense as a percent of premiums revenues.</font></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Operating Cost Ratio </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">            Consolidated</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GAAP&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.3% to 11.7%</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ratio calculation&#58; operating costs excluding depreciation and amortization as a percent of revenues excluding investment income.</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Segment Results</font></td></tr><tr style="height:26pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Insurance segment income from operations</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GAAP&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1.5 billion to $2.0 billion</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;<br></font><font style="font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CenterWell segment Non-GAAP income from operations excludes the projected impact of segment depreciation and amortization.</font></td></tr><tr style="height:45pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CenterWell segment income from operations</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GAAP&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> $1.0 billion to $1.5 billion</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Non-GAAP&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> $1.2 billion to $1.7 billion</font></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Effective Tax Rate</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GAAP&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  approximately 25.0%</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Weighted Avg. Share Count for Diluted EPS</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">approximately 121.5 million</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cash flows from operations</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GAAP&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> $2.4 billion to $2.9 billion</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Capital expenditures</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">approximately $650 million</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12</font></div></div></div><div id="i900a727b98754728b9e3a3880bb98a4e_106"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:40pt;font-weight:400;line-height:120%">Humana Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:40pt;font-weight:400;line-height:120%">Statistical Schedules</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:40pt;font-weight:400;line-height:120%">and</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:40pt;font-weight:400;line-height:120%">Supplementary Information</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:40pt;font-weight:400;line-height:120%">1Q25 Earnings Release</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S-1</font></div></div></div><div id="i900a727b98754728b9e3a3880bb98a4e_109"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center;text-indent:-36pt"><font><br></font></div><div style="text-align:center;text-indent:-36pt"><font><br></font></div><div style="text-align:center;text-indent:-36pt"><font><br></font></div><div style="text-align:center;text-indent:-36pt"><font><br></font></div><div style="text-align:center;text-indent:-36pt"><font><br></font></div><div style="text-align:center;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.833%"><tr><td style="width:1.0%"></td><td style="width:23.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.692%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Humana Inc.<br>Statistical Schedules and Supplementary Information <br>1Q25 Earnings Release  </font></td></tr><tr style="height:5pt"><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 19pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(S-3)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Summary of Results - Consolidated and Segment - Quarter</font></td></tr><tr><td colspan="3" style="padding:2px 19pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(S-4)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Consolidated Statements of Income - Quarter </font></td></tr><tr><td colspan="3" style="padding:2px 19pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(S-5)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Consolidated Balance Sheets</font></td></tr><tr><td colspan="3" style="padding:2px 19pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(S-6)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Consolidated Statements of Cash Flows - YTD</font></td></tr><tr><td colspan="3" style="padding:2px 19pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(S-7) - (S-8)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Consolidating Statements of Income - Quarter</font></td></tr><tr><td colspan="3" style="padding:2px 19pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(S-9) </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Membership Detail</font></td></tr><tr><td colspan="3" style="padding:2px 19pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(S-10)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Premiums and Services Revenue Detail</font></td></tr><tr><td colspan="3" style="padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(S-11) - (S-13)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CenterWell Segment - Pharmacy Solutions, Primary Care, &#38; Home Solutions</font></td></tr><tr><td colspan="3" style="padding:2px 19pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(S-14)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Footnotes</font></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S-2</font></div></div></div><div id="i900a727b98754728b9e3a3880bb98a4e_115"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.270%"><tr><td style="width:1.0%"></td><td style="width:62.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.134%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.135%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Humana Inc. Summary of Results<br></font><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions, except per share amounts)</font></div></td><td colspan="3" style="background-color:#5c9a1b;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q25 (a)</font></td><td colspan="3" style="background-color:#5c9a1b;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q24 (a)</font></td></tr><tr><td colspan="9" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSOLIDATED</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues </font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$32,112</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$29,611</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues - Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$32,112</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$29,332</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax results</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$1,691</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,014</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax results - Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$1,893</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,191</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$10.30</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.11</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS - Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$11.58</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7.23</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit ratio</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87.0</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.9&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cost ratio</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cost ratio - Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows </font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$331</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$423</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parent company cash and short term investments</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$1,234</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$509</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt-to-total capitalization</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42.8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.1&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Days in Claims Payable (DCP)</font></td><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.8</font></td><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.5</font></td></tr><tr><td colspan="9" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">INSURANCE SEGMENT</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$30,937</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$28,699</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues - Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$30,937</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$28,420</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit ratio</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.3&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit ratio - Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.4&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cost ratio</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cost ratio - Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$1,574</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$898</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations - Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$1,578</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$903</font></td></tr><tr><td colspan="9" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CENTERWELL SEGMENT</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$5,095</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,818</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cost ratio</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">91.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.0&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$392</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$282</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations - Adjusted (non-GAAP) (c)</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$451</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$335</font></td></tr></table></div><div style="padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Refer to the &#34;Footnotes&#34; section included in the previous narrative portion of this release (beginning on page 7) for further explanation of disclosures for Adjusted (non-GAAP) financial measures, as well as reconciliations.</font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S-3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Humana Inc.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Consolidated Statements of Income (Unaudited)</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Dollars in millions, except per common share results</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.791%"><tr><td style="width:1.0%"></td><td style="width:60.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.856%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">For&#160;the&#160;three&#160;months&#160;ended&#160;<br>March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Premiums</font></td><td style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">30,514</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28,261&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Services</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1,334</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,062&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Investment income</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">264</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">288&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total revenues</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">32,112</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,611&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Benefits</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">26,535</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25,124&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating costs</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3,380</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,042&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">183</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">209&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total operating expenses</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">30,098</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28,375&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Income from operations</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2,014</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,236&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">160</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">159&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other expense, net</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">163</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">63&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Income before income taxes and equity in net losses</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1,691</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,014&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provision from income taxes</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">406</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">251&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Equity in net losses (A)</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(43)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(24)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Net income</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1,242</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">739&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Net income attributable to Humana</font></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1,244</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">741&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic earnings per common share</font></td><td style="border-left:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.31</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-left:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.13&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Diluted earnings per common share</font></td><td style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.30</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.11&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing basic earnings per common share (000&#8217;s)</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">120,666</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,978&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing diluted earnings per common share (000&#8217;s)</font></td><td colspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">120,844</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,268&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S-4</font></div></div></div><div id="i900a727b98754728b9e3a3880bb98a4e_121"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humana Inc.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Balance Sheets (Unaudited)</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Dollars in millions, except share amounts</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.062%"><tr><td style="width:1.0%"></td><td style="width:72.655%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.023%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</font></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December&#160;31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,250</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,221&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment securities</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17,888</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,214&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivables, net</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,459</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,704&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,825</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,676&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34,422</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,815&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,427</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,532&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term investment securities</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">410</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">421&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity method investments</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">659</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">697&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,631</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,631&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term assets</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,381</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,383&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</font></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50,930</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,479&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities and Stockholders&#8217; Equity</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits payable</font></td><td style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,451</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,440&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade accounts payable and accrued expenses</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,380</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,259&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Book overdraft</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">370</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unearned revenues</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">265</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">260&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">577</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">577&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18,043</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,939&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,729</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,144&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,339</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,951&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total liabilities</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">33,111</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,034&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders&#8217; equity&#58;</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $1 par&#59; 10,000,000 shares authorized, none issued</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $0.16 2&#47;3 par&#59; 300,000,000 shares authorized&#59; 198,719,321 issued at March 31, 2025</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">33</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital in excess of par value</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,497</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,463&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained earnings</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29,453</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,317&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(868)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,067)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock, at cost, 78,025,846 shares at March 31, 2025</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(14,364)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,371)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total stockholders&#8217; equity</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17,751</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,375&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interests</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">68</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total equity</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17,819</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,445&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total liabilities and equity</font></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50,930</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,479&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt-to-total capitalization ratio</font></td><td colspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">42.8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.9&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S-5</font></div></div></div><div id="i900a727b98754728b9e3a3880bb98a4e_124"></div><hr style="page-break-after:always"><div style="min-height:31.5pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humana Inc. </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows (Unaudited) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Dollars in millions </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.979%"><tr><td style="width:1.0%"></td><td style="width:66.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.965%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the three months ended March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</font></td><td style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,242</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">739&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities&#58;</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on investment securities, net</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity in net losses</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">200</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of property and equipment</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of effect of businesses acquired and disposed&#58;</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivables</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,755)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,890)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(686)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits payable</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,011</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,488&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other liabilities</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">193</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(422)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unearned revenues</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash provided by operating activities</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">331</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">423&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions, net of cash and cash equivalents acquired</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment, net</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(95)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(177)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in securities lending collateral receivable</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(175)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of investment securities</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(827)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,259)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maturities of investment securities</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">889</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">645&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sales of investment securities</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">522</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">391&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash provided by (used in) investing activities</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">314</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(414)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Payments) receipts from contract deposits, net</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(35)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of senior notes, net</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,481</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,232&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayments from issuance of commercial paper, net</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(644)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt issue costs</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in book overdraft</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(33)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock repurchases</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(717)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends paid</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(108)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(109)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in securities lending payable</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">175</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in rebate factor payable</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(68)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net </font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(12)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash provided by financing activities</font></td><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,384</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,207&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase in cash and cash equivalents</font></td><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,029</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,216&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</font></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,221</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,694&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and cash equivalents at end of period </font></td><td style="border-bottom:3pt double #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,250</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,910&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S-6</font></div></div></div><div id="i900a727b98754728b9e3a3880bb98a4e_130"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Humana Inc.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Consolidating Statements of Income&#8212;For the three months ended March 31, 2025 (Unaudited)</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In millions </font><font style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </font></div><div><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.625%"><tr><td style="width:1.0%"></td><td style="width:44.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Insurance</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CenterWell</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Eliminations&#47;<br>Corporate</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues&#8212;external customers Premiums&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Medicare Advantage</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,681&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,681&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Medicare Advantage</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,322&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,322&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,448&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,448&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Medicare</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,451&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,451&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State-based contracts and other</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,568&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,568&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty benefits</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Medicare Supplement</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total premiums</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,514&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,514&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Services revenue&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home solutions</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary care</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy solutions</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Military services and other</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total services revenue</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,334&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues&#8212;external customers</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,766&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,848&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,013&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,014)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,937&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,095&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,920)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,112&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,675&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,535&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,534&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,644&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,798)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,380&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,363&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,703&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,968)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,098&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income from operations</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,574&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,014&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit ratio</font></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.4&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.0&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating cost ratio</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="margin-bottom:1pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S-7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Humana Inc.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Consolidating Statements of Income&#8212;For the three months ended March 31, 2024 (Unaudited)</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In millions</font></div><div><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.625%"><tr><td style="width:1.0%"></td><td style="width:44.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Insurance</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CenterWell</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Eliminations&#47;<br>Corporate</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues&#8212;external customers Premiums&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Medicare Advantage</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,448&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,448&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Medicare Advantage</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,989&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,989&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Medicare</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,258&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,258&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State-based contracts and other </font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,311&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,311&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial fully-insured</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty benefits</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Supplement</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total premiums</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,261&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,261&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Services revenue&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home solutions</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary care</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy solutions</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Military services and other</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial ASO</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total services revenue</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,062&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues&#8212;external customers</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,536&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,323&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,031&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,032)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,699&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,818&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,906)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,611&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,251&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,124&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,364&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,483&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,805)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,042&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,801&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,536&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,962)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,375&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income from operations</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,236&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit ratio</font></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.3&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.9&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating cost ratio</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="margin-bottom:1pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S-8</font></div></div></div><div id="i900a727b98754728b9e3a3880bb98a4e_136"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Humana Inc.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Membership Detail  (Unaudited)     </font><font style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">In thousands</font></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.041%"><tr><td style="width:1.0%"></td><td style="width:36.123%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.199%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.199%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.199%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.204%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</font></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average 1Q25</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2024</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Membership&#58;</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Individual Medicare Advantage*</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,215.8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,226.9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,548.9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,661.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Group Medicare Advantage</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">572.6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">574.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">551.5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">545.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Medicare Advantage</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,788.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,801.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,100.4&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,207.5&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,433.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,416.9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,347.0&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,288.2&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Medicare</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,221.5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,218.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,447.4&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,495.7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Supplement</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">420.5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">413.6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">323.2&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">377.3&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State-based contracts and other</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,608.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,597.8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,261.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,459.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Military services</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,588.9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,588.9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,955.3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,009.1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total excluding employer group commercial medical</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14,839.0</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14,818.5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,987.3&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,342.0&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fully-insured commercial medical</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.7&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ASO commercial</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.7&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total employer group commercial medical</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.4&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Medical Membership</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14,839.0</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14,818.5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,174.7&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,347.1&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Specialty Membership&#58;</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dental&#8212;fully-insured (B)</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,095.9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,097.7</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,099.0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,054.5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dental&#8212;ASO</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">312.8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">313.7</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303.8&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">301.3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Dental</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,408.7</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,411.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,402.8&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,355.8&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vision</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,906.0</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,907.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,884.3&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,843.6&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other supplemental benefits</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">373.7</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">372.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">366.1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">362.6&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Specialty Membership</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,688.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,690.9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,653.2&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,562.0&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Member Mix<br>March 31, 2025</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2024</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Member Mix<br>March 31, 2024</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Individual Medicare Advantage Membership</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HMO</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,658.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,848.6&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PPO&#47;PFFS</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,557.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,700.3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Individual Medicare Advantage</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,215.8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">100</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,548.9&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Individual Medicare Advantage Membership</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shared Risk (C)</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,930.6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">37</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,051.9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Path to Risk (D)</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,571.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,785.4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Value-based</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,501.7</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">67</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,837.3&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,714.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">33</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,711.6&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Individual Medicare Advantage</font></td><td colspan="2" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,215.8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">100</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,548.9&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Individual Medicare Advantage membership includes</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> 799,100 </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Dual Eligible Special Need Plans (D-SNP) members as of March 31, 2025, a net decrease of 123,100, or 13 percent, from 922,200 as of March 31, 2024, and down 138,000, or </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15 percent</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, from 937,100 as of December 31, 2024.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S-9</font></div></div></div><div id="i900a727b98754728b9e3a3880bb98a4e_139"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div id="i900a727b98754728b9e3a3880bb98a4e_145"></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Humana Inc. </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Premiums and Services Revenue Detail (Unaudited)</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dollars in millions, except per member per month&#59; includes intersegment revenues </font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.708%"><tr><td style="width:1.0%"></td><td style="width:44.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.019%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.361%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For&#160;the&#160;three&#160;months&#160;ended&#160;<br>March 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Per&#160;Member&#160;per&#160;Month&#160;(I)<br>For&#160;the&#160;three&#160;months&#160;ended&#160;March 31,</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Insurance</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Individual Medicare Advantage</font></td><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">22,681</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,448&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,446</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,351&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Group Medicare Advantage</font></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,322</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,989&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,347</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,202&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</font></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,448</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">821&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">200</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State-based contracts and other (E)</font></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,568</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,311&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">709</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">576&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial fully-insured (F)</font></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">565&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty benefits (G)</font></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">244</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">239&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare Supplement</font></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">251</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">202</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Military and other (H)</font></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">253</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">252&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial ASO</font></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total </font></td><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">30,767</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,537&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CenterWell</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy solutions</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,844</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,828&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Primary care</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,419</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,170&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Home solutions </font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">832</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">820&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</font></td><td colspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,095</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,818&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S-10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Humana Inc.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:120%">CenterWell Segment - Pharmacy Solutions (Unaudited) </font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.062%"><tr><td style="width:1.0%"></td><td style="width:20.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.503%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:24.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">For&#160;the&#160;three&#160;months&#160;ended<br>March 31, 2025</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">For&#160;the&#160;three&#160;months&#160;ended<br>March 31, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">For&#160;the&#160;three&#160;months&#160;ended<br>December 31, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Generic Dispense Rate</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 49.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total Medicare</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">91.0</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">91.0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">90.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Mail-Order Penetration</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 49.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total Medicare</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">26.0</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">29.0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">27.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><font><br></font></div><div style="padding-left:99pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S-11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Humana Inc.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:120%">CenterWell Segment - Primary Care (J) (Unaudited) </font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.041%"><tr><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.336%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.336%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.336%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.336%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.336%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.336%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.336%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.336%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">As of March 31, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">As of March 31, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Year-over-Year Growth</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Primary</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Primary</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Primary</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Center</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Care</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patients</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Center</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Care</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patients</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Center</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Care</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patients</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Count</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Providers</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Served (K)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Count</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Providers</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Served (K)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Count</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Providers</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Served</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">De novo</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">136&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">345</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">92,000&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">113&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">275</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">52,000&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.4&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25.5&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">76.9&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Wholly-owned</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">193</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">759</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">254,200&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">186</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">625</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">203,100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Independent Physician Associations</font></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">71,600&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">62,900&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">329</font></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,104&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">417,800&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">299</font></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">900&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">318,000&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.0&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22.7&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31.4&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="margin-bottom:1pt;text-align:center"><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.020%"><tr><td style="width:1.0%"></td><td style="width:17.412%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:4.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.866%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">As of December 31, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sequential Growth</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Primary</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Primary</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Center</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Care</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patients</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Center</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Care</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patients</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Count</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Providers</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Served (K)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Count</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Providers</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Served</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">De novo</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">133&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">327</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">79,400&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.3&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.5&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.9&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Wholly-owned</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">211</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">675</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">246,500&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(8.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Independent Physician Associations</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">64,600&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">344</font></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,002&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">390,500&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.4)</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.2&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.0&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="margin-bottom:1pt;text-align:center"><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S-12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Humana Inc.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:120%">CenterWell Segment - Home Solutions (Unaudited) </font></div><div style="margin-bottom:1pt;text-align:center"><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.145%"><tr><td style="width:1.0%"></td><td style="width:29.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">For the three months ended<br>March 31, 2025</font></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">For the three months ended<br>March 31, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">Year-over-Year Growth</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">Episodic Admissions (L)</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">82,146&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">84,260&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">(2.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">Total Admissions - Same Store (M)</font></td><td colspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">108,715&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">107,827&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">0.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="margin-bottom:1pt;text-align:center"><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S-13</font></div></div></div><div id="i900a727b98754728b9e3a3880bb98a4e_157"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Humana Inc.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Footnotes to Statistical Schedules and Supplementary Information</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1Q25 Earnings Release </font></div><div><font><br></font></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.87pt">Net losses</font><font style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">associated with the company's non-consolidated minority interest investments.</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.25pt">Fully-insured dental membership as reported does not include Humana members that have a Medicare Advantage plan that includes an embedded dental benefit. </font></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">C.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.37pt">In certain circumstances, the company contracts with providers to accept financial risk for a defined set of Medicare Advantage membership. For these Downside Risk arrangements, the provider is measured against a medical expense ratio target and the company may share savings from reduction to the total cost of care of the defined membership. The result is a high level of engagement on the part of the provider. Under these arrangements, the company may contract with providers to accept partial, full, or global financial risk. In certain instances (capitated shared risk) of these arrangements, the company may choose to prepay these providers a monthly fixed-fee per member to coordinate substantially all of the medical care for their Medicare Advantage members assigned or attributed to their provider panel, including some health benefit administrative functions and claims processing.</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">D.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:8.47pt">A Path to Risk provider is one who has a high level of engagement and has contracted with the company to participate in an Upside Only&#47;Shared Savings total cost of care arrangement and&#47;or in one of Humana&#8217;s Quality Bonus programs (Model Practice), through which the company rewards the provider for achieving quality and utilization targets. Providers who are contracted in an Upside Only&#47;Shared Savings arrangement may receive a portion of achieved surpluses when the actual cost of the medical services provided to patients assigned or attributed to their panel is less than the agreed upon medical expense targets. These contracts may also include a Downside Risk trigger (future date or membership threshold) which has not yet been met.</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">E.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.86pt">Per Member per Month (PMPM) shown reflects only Medicaid premiums and average Medicaid membership for the period&#59; includes impact of dual eligible demonstration members. </font></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">F.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.18pt">Fully-insured commercial medical premiums also include stop-loss premiums associated with the commercial ASO product&#59; for purposes of the PMPM metric, the commercial ASO stop-loss premiums have been excluded.</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">G.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.3pt">Specialty per member per month is computed based on reported specialty premiums and average fully-insured specialty membership for the period.  </font></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">H.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.38pt">The amounts primarily reflect services revenues under the TRICARE East Region contract that generally are contracted on a per-member basis. </font></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.46pt">Computed based on average membership for the period (i.e. monthly ending membership during the period divided by the number of months in the period).</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">J.</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.73pt">De novo </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">refers to all new centers opened or acquired since 2020 under a WCAS joint venture</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">.  Wholly-owned </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">refers to all centers outside a WCAS joint venture. </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">K.</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.52pt">Represents Medicare Advantage (MA) risk, MA path to risk, MA value-based, Direct Contracting Entity, and Accountable Care Organization patients. </font><font style="background-color:#ffffff;color:#ee2724;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">L.</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.61pt">Reflects patient admissions under the Patient Driven Groupings Model (PDGM) payment model.</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">M.</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.83pt">Reflects all patient admissions regardless of reimbursement model. Same store is defined as care centers that have been owned and operated at least the last twelve months and startups that are an expansion of a same store care center. </font></div><div style="padding-left:9pt"><font><br></font></div><div style="padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S-14</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>a1q2025humanaincpreparedre.htm
<DESCRIPTION>EX-99.3
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ibfad7ee30e0a4219af25be7e2190819d_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Humana Inc. First Quarter 2025 Prepared Management Remarks</font><font style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">04&#47;30&#47;2025</font></div></div><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:72px;margin-bottom:5pt;vertical-align:text-bottom;width:238px"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Please view these remarks in conjunction with our 1Q 2025 earnings release that can be found on our website at </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.humana.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> under the Investors section, or via the following link&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;humana.gcs-web.com&#47;financial-information&#47;quarterly-results</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12.5pt;font-weight:400;line-height:120%;text-decoration:underline">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We also invite you to listen to our live question and answer webcast with our President and Chief Executive Officer, Jim Rechtin, Chief Financial Officer, Celeste Mellet, and President of Insurance, George Renaudin, which will begin today at 8&#58;00 a.m. Eastern Time and will be available at via the following link&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;humana.gcs-web.com&#47;events-and-presentations&#47;upcoming-events</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. For those unable to listen to the live event, the archive will be available in the Historical Webcasts and Presentations section of the Investor Relations page via the following link&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;humana.gcs-web.com&#47;events-and-presentations</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Cautionary Statement </font></div><div style="margin-bottom:5pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Certain of the matters discussed in these prepared remarks are forward-looking and are subject to a number of risks, uncertainties and assumptions.  Actual results could differ materially.</font></div><div style="margin-bottom:5pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investors are advised to read the detailed risk factors discussed in our latest Form 10-K, our other filings with the Securities and Exchange Commission, and our 1Q 2025 earnings release as they relate to forward-looking statements along with other risks discussed in our SEC filings. We undertake no obligation to publicly address or update any forward-looking statements in future filings or communications regarding our business or results. </font></div><div style="margin-bottom:5pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Today&#8217;s release, our historical financial news releases and our filings with the SEC are all also available on our Investor Relations site.  </font></div><div style="margin-bottom:5pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">These remarks include financial measures that are not in accordance with generally accepted accounting principles, or GAAP. </font></div><div style="margin-bottom:5pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Management's explanation for the use of these non-GAAP measures and reconciliations of GAAP to non-GAAP financial measures are included in today&#8217;s release which can be found via the following link&#58;  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;humana.gcs-web.com&#47;financial-information&#47;quarterly-results</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:5pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Finally, any references to earnings per share or EPS made within these remarks refer to diluted earnings per common share. </font></div><div style="margin-bottom:5pt;text-align:justify;text-indent:21.6pt"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify;text-indent:21.6pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><div id="ibfad7ee30e0a4219af25be7e2190819d_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Humana Inc. First Quarter 2025 Prepared Management Remarks</font><font style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">04&#47;30&#47;2025</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Management Commentary</font></div><div style="margin-bottom:3pt;padding-right:-4.3pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:20.00pt">Key Messages&#58;</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-4.3pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">We are </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">pleased with a solid start to 2025. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our first quarter Insurance segment benefit ratio of 87.4% reflects </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">medical cost trends that developed in line with our expectations, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">while our </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">first quarter Adjusted EPS was ahead of expectations </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">largely driven by&#58;</font></div><div style="margin-bottom:6pt;padding-left:54pt;padding-right:-4.3pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">A shift in expected timing of certain administrative expenses and incremental investments, and</font></div><div style="margin-bottom:6pt;padding-left:54pt;padding-right:-4.3pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">Outperformance in CenterWell, inclusive of certain timing related items</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-4.3pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Based on results to date, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">we reaffirmed our 2025 guidance</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">including</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#58;</font></div><div style="margin-bottom:6pt;padding-left:54pt;padding-right:-4.3pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">Adjusted EPS outlook of &#8216;approximately $16.25&#8217; </font></div><div style="margin-bottom:6pt;padding-left:54pt;padding-right:-4.3pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">Insurance segment benefit ratio guidance range of 90.1% to 90.5%</font></div><div style="margin-bottom:6pt;padding-left:54pt;padding-right:-4.3pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">Full year 2025 Medicare and Medicaid membership expectations</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">We</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> remain committed to achieving individual Medicare Advantage (MA) pretax margin of &#8216;at least 3%&#8217; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">over time and </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">remain confident in our expectation </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">that our</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> 2025 MA pricing will drive the intended underlying margin improvement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">We</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> continue to anticipate a &#8220;few hundred million dollars&#8221; of incremental investments in 2025</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> to </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">improve member and patient outcomes and support operational excellence, positioning the company for long-term success</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">Early returns on investments made in 2024 and first quarter 2025 are tracking in line with expectations </font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Efforts to strengthen our Stars program</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">are progressing as anticipated</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with initiatives expected to impact across key measures as we </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">focus on a return to a sustainable industry leading position</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-4.3pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">We</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> further expanded our CenterWell platform in the first quarter</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, including&#58;</font></div><div style="margin-bottom:6pt;padding-left:54pt;padding-right:-4.3pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">Growth of 27,300 patients, or 7%, in CenterWell Primary Care as compared to December 31, 2024</font></div><div style="margin-bottom:6pt;padding-left:126pt;padding-right:-4.3pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.97pt">CenterWell Primary Care patient growth includes 12,600 patients, or 16% growth, in our de novo centers as compared to December 31, 2024</font></div><div style="margin-bottom:6pt;padding-left:54pt;padding-right:-4.3pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">CenterWell Pharmacy selected as the fulfillment pharmacy for NovoCare</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#174;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Pharmacy&#8217;s weight loss medication for cash pay customers </font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-4.3pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">We are</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> strategically expanding our Medicaid platform </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">with Illinois&#8217; intent to award Humana their new Fully Integrated Dual Eligible (FIDE) Special Needs Plan (SNP) program which is expected to start in 2026</font></div><div style="margin-bottom:6pt;padding-left:54pt;padding-right:-4.3pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">The Illinois program includes a greenfield DSNP entry opportunity in a core Humana MA market with over 450,000 dual-eligibles </font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-4.3pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Looking ahead, the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2026 final MA rate notice better reflects the medical cost trend environment and should enable greater stability within the industry as it serves </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the 34 million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> seniors who rely on the MA program for high-quality, affordable care and better health outcomes</font></div><div style="margin-bottom:6pt;padding-left:54pt;padding-right:-4.3pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">We will continue to work with the Administration and policymakers in Congress to strengthen the MA program and protect the choices and benefits that seniors rely on</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-4.3pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">We look forward to sharing more on our mid- and longer-term outlook at our 2025 Investor Conference on June 16, 2025</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Humana Inc. First Quarter 2025 Prepared Management Remarks</font><font style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">04&#47;30&#47;2025</font></div></div><div style="margin-bottom:7.2pt;padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:120%">Detailed Discussion&#58;</font></div><div style="margin-bottom:7.2pt;padding-right:-4.5pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:120%">Individual Medicare Advantage (MA) </font></div><div style="margin-bottom:7.2pt;padding-left:54pt;padding-right:-4.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">1Q25 year to date (YTD) membership decline of approximately 446,000 is in line with our expectations. We continue to anticipate a full year (FY) 2025 decline of approximately 550,000 members</font></div><div style="margin-bottom:7.2pt;padding-left:90pt;padding-right:-4.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11.5pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:11.1pt">Membership losses largely driven by our decision to exit certain unprofitable plans and counties, which impacted approximately 560,000 members  </font></div><div style="margin-bottom:7.2pt;padding-left:126pt;padding-right:-4.5pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Wingdings',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:12.74pt">The plan and county exits have been partially offset by net sales activity (gross sales, less voluntary terminations and mortality), including the recapture of approximately 40% of the members impacted by plan exits into other Humana MA plans</font></div><div style="margin-bottom:7.2pt;padding-left:90pt;padding-right:-4.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11.5pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:11.1pt">We remain confident in our pricing strategy as we prioritize serving membership which will drive sustainable, long-term value creation</font></div><div style="margin-bottom:7.2pt;padding-left:54pt;padding-right:-4.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">1Q25 revenue is in line with our expectations and we continue to expect our premium yield to be in the high single digits for the full year, driven in large part by an increased direct subsidy due to the Inflation Reduction Act (IRA)</font></div><div style="margin-bottom:7.2pt;padding-left:54pt;padding-right:-4.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">While it remains early in the year, available information to date suggests medical and Rx cost trends are in line with our expectations</font></div><div style="margin-bottom:7.2pt;padding-left:72pt;padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:7.2pt;padding-right:-4.5pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:120%">Group MA</font></div><div style="margin-bottom:7.2pt;padding-left:54pt;padding-right:-4.3pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">1Q25 YTD membership growth of approximately 27,000 is in line with our expectations and we continue to expect membership to be relatively flat year over year for FY 2025</font></div><div style="margin-bottom:7.2pt;padding-left:54pt;padding-right:-4.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">Group MA is performing as anticipated to date, with revenue and medical cost trends developing in line with our expectations</font></div><div style="margin-bottom:7.2pt;padding-left:54pt;padding-right:-4.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">As shared on our fourth quarter 2024 earnings call (in February 2025), Group MA had margin pressure in 2024 that, as expected, continued into 2025 due to multi-year pricing cycles</font></div><div style="margin-bottom:7.2pt;padding-left:54pt;padding-right:-4.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">We remain focused on improving Group MA margins through renewal cycles to reflect the current reimbursement levels and cost trends, with the opportunity to significantly improve performance through re-contracting</font><font style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">in 2026 and beyond</font></div><div style="margin-bottom:7.2pt;padding-right:-4.5pt;text-align:justify;text-indent:18pt"><font><br></font></div><div style="margin-bottom:7.2pt;padding-right:-4.5pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:120%">Stand-Alone Part D (PDP)</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">1Q25 YTD membership growth of approximately 145,000 is in line with expectations&#59; we continue to anticipate FY 2025 membership growth of approximately 200,000</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">We are closely monitoring PDP performance given the magnitude of IRA changes implemented this year and the potential impact on member behavior</font></div><div style="margin-bottom:6pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11.5pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:11.1pt">PDP membership mix, Rx trends, and member behavior are in line with our expectations to date</font></div><div style="margin-bottom:7.2pt;padding-right:-4.5pt;text-align:justify;text-indent:18pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Humana Inc. First Quarter 2025 Prepared Management Remarks</font><font style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">04&#47;30&#47;2025</font></div></div><div style="margin-bottom:7.2pt;padding-right:-4.5pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:120%">Medicaid</font></div><div style="margin-bottom:7.2pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">1Q25 YTD membership growth of approximately 106,000, or 8%, compared to December 31, 2024, is in line with expectations, largely driven by additional membership allocation in Kentucky</font></div><div style="margin-bottom:7.2pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">Continue to anticipate growth of 175,000 to 250,000 members for FY 2025, representing an increase of approximately 16% for the year at the midpoint, including the anticipated implementation of the Virgina contract later this year </font></div><div style="margin-bottom:7.2pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">Early indicators suggest medical cost trends are in line with our expectations</font></div><div style="margin-bottom:7.2pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">We continue to anticipate modest improvement in our Medicaid margin in 2025 as additional states progress through the J curve and rates are updated to reflect the acuity level of members and trend experience related to the Public Health Emergency (PHE) unwind</font></div><div style="margin-bottom:7.2pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11.5pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:11.1pt">Rate updates for approximately 75% of Medicaid revenue are projected as final for 2025</font></div><div style="margin-bottom:7.2pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">Strategically expanding our Medicaid platform with Illinois&#8217; intent to award Humana their new FIDE SNP program which is expected to start in 2026</font></div><div style="margin-bottom:7.2pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11.5pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:11.1pt">The Illinois program includes a greenfield DSNP entry opportunity in a core Humana MA market with over 450,000 dual-eligibles </font></div><div style="margin-bottom:7.2pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11.5pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:11.1pt">This award includes a distinct, standalone managed long-term services and supports contract, expected to start in 2027</font></div><div style="margin-bottom:7.2pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:174%">CenterWell</font></div><div style="margin-bottom:7.2pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">CenterWell outperformed our expectations in the quarter, inclusive of timing related items. </font></div><div style="margin-bottom:7.2pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:174%;text-decoration:underline">Primary Care</font></div><div style="margin-bottom:7.2pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">Serving nearly 418,000 patients as of March 31, 2025, an increase of 27,300 patients, or 7%, from December 31, 2024.   Patient growth for the first quarter includes&#58;</font></div><div style="margin-bottom:7.2pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11.5pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:11.1pt">12,600 patients, or 16% growth, in our de novo centers</font></div><div style="margin-bottom:7.2pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11.5pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:11.1pt">7,700 patients, or 3% growth, in our more mature wholly-owned centers&#59; and</font></div><div style="margin-bottom:7.2pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11.5pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:11.1pt">7,000 patients, or nearly 11%, growth in our Independent Physician Associations (IPA) business</font></div><div style="margin-bottom:7.2pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">Aiding this patient growth is improved patient satisfaction, which increased Net Promoter Score (NPS) 120 basis points year over year</font></div><div style="margin-bottom:7.2pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11.5pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:11.1pt">Improvement supported by enhanced patient experience data intelligence which creates the ability to convert fragmented feedback into consistent, actionable insights at scale     </font></div><div style="margin-bottom:7.2pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">Continue to anticipate FY 2025 net patient growth of 30,000 to 50,000, reflecting approximately 10% growth at the midpoint, driven by organic growth, modest M&#38;A, and additional growth with Original Medicare as a part of our ACO Reach program</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Humana Inc. First Quarter 2025 Prepared Management Remarks</font><font style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">04&#47;30&#47;2025</font></div></div><div style="margin-bottom:7.2pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">Operating 329 centers as of March 31, 2025, representing growth of 30 centers, or 10%, year over year, while representing a reduction of 15 centers, or 4%, from December 31, 2024</font></div><div style="margin-bottom:7.2pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11.5pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:11.1pt">Reduction in total centers during 1Q25 YTD is driven by ongoing center footprint optimization in connection with acquisition activity during 2024</font></div><div style="margin-bottom:7.2pt;padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Wingdings',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:12.74pt">7 de novo centers were added during 1Q25, more than offset by the impact of center consolidations as part of the footprint optimization described above</font></div><div style="margin-bottom:7.2pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">We still anticipate we will mitigate the ultimate impact of the v28 risk model changes over the three-year phase in through a multi-pronged plan including numerous operational efficiencies such as centralizing and streamlining administrative functions, standardizing the clinic operating model, and improving clinician productivity to increase capacity</font></div><div style="margin-bottom:7.2pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11.5pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:11.1pt">The impact of v28 and our related mitigation efforts are tracking in line with expectations to date</font></div><div style="margin-bottom:7.2pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">Continue to anticipate largely flat margins year over year with the impact of the ongoing phase in of v28 and the addition of centers at various stages of maturation expected to be offset by&#58;</font></div><div style="margin-bottom:7.2pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11.5pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:11.1pt">advancement of our ongoing v28 mitigation activities, and </font></div><div style="margin-bottom:7.2pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11.5pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:11.1pt">further maturation of our existing centers which are progressing through the J curve </font></div><div style="margin-bottom:7.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:174%;text-decoration:underline">Home</font></div><div style="margin-bottom:7.2pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">Within our CenterWell Home Health fee-for-service business, 1Q25 same store admissions grew approximately 1% year over year</font></div><div style="margin-bottom:7.2pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11.5pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:11.1pt">January admission growth was pressured due to MA plan change activity for certain patients during the recently completed MA Annual Election Period (AEP).  Admission activity ramped significantly throughout the quarter such that admission growth was in line with expectations as we exited the first quarter </font></div><div style="margin-bottom:7.2pt;padding-left:58.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:18.48pt">We continue to anticipate a &#8216;mid to high&#8217; single digit increase in home health admissions for FY 2025</font></div><div style="margin-bottom:7.2pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">OneHome expanded the percentage of members in some form of value-based home health model by 12% in 1Q25, as compared to December 31, 2024, and anticipates 15% expansion for FY 2025 </font></div><div style="margin-bottom:7.2pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">Our comprehensive initiative to drive productivity and efficiency within our home operating model to offset reimbursement pressure is progressing as anticipated and driving the intended results </font></div><div style="margin-bottom:7.2pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Pharmacy</font></div><div style="margin-bottom:7.2pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">Pharmacy results in the first quarter slightly exceeded expectations due to favorable drug mix</font></div><div style="margin-bottom:7.2pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">We were pleased to recently be selected as the fulfillment pharmacy for NovoCare</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#174;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> Pharmacy&#8217;s weight loss medication for cash pay customers, consistent with our focus on expanding agnostic activity</font></div><div style="margin-bottom:7.2pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11.5pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:11.1pt">This activity was contemplated in our original FY 2025 guidance issued on February 11, 2025</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Humana Inc. First Quarter 2025 Prepared Management Remarks</font><font style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">04&#47;30&#47;2025</font></div></div><div style="padding-right:-4.3pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:120%">Earnings Seasonality</font></div><div style="padding-right:-4.3pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:7.2pt;padding-left:54pt;padding-right:-4.3pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">We expect second quarter earnings to be approximately 35% of expected full year 2025 Adjusted earnings </font></div><div style="margin-bottom:7.2pt;padding-left:54pt;padding-right:-4.3pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">Second quarter Insurance segment benefit ratio expected to be approximately 90%  </font></div><div style="margin-bottom:7.2pt;padding-left:54pt;padding-right:-4.3pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">Based off historical precedent, we continue to assume the Doc Fix will occur for 2025 either as part of the reconciliation exercise or the government funding bill </font></div><div style="margin-bottom:7.2pt;padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:7.2pt;padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:174%">Capital Deployment &#38; Balance Sheet</font></div><div style="margin-bottom:7.2pt;padding-left:49.65pt;padding-right:-4.3pt;text-align:justify;text-indent:-22.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:18.28pt">As previously shared, we will remain prudent in our near-term capital deployment approach as we fully assess our Stars mitigation plans and until we finalize our 2026 MA pricing strategy </font></div><div style="margin-bottom:7.2pt;padding-left:85.65pt;padding-right:-4.3pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11.5pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:11.1pt">As a result, our current 2025 outlook does not contemplate share repurchase activity </font></div><div style="margin-bottom:7.2pt;padding-left:85.65pt;padding-right:-4.3pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11.5pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:11.1pt">We will re-evaluate our capital deployment plans throughout the year, taking a balanced approach to evaluating capital investments and returns</font></div><div style="margin-bottom:7.2pt;padding-left:49.5pt;padding-right:-4.3pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:18.48pt">We raised $1.5 billion in the debt markets during the first quarter, which covers our maturities through the end of 2026</font></div><div style="margin-bottom:7.2pt;padding-left:81pt;padding-right:-4.3pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11.5pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:11.1pt">Debt to capitalization as of March 31, 2025 is 42.8% and we continue to target a debt to capitalization ratio of approximately 40% over the long term</font></div><div style="margin-bottom:7.2pt;padding-left:45pt;padding-right:-4.3pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">Accelerating our efforts to increase the efficiency of our balance sheet and fortify our foundation</font></div><div style="margin-bottom:7.2pt;padding-left:81pt;padding-right:-4.3pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11.5pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:11.1pt">We believe there is substantial opportunity to continue to increase the efficiency of our balance sheet and free up cash which will enhance operational performance and drive increased shareholder value over the long term </font></div><div style="margin-bottom:7.2pt;padding-left:72pt;padding-right:-4.3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:7.2pt;padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:700;line-height:174%;text-decoration:underline">Conclusion</font></div><div style="margin-bottom:7.2pt;padding-left:54pt;padding-right:-9.35pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">Humana had a solid start to 2025 and we were pleased to affirm our full year guidance  </font></div><div style="margin-bottom:7.2pt;padding-left:54pt;padding-right:-9.35pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">Looking ahead, we remain committed to returning to industry leading Stars performance and achieving individual MA pretax margin of &#8216;at least 3%&#8217; </font></div><div style="margin-bottom:7.2pt;padding-left:90pt;padding-right:-9.35pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11.5pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:11.1pt">2025 represents a critical step on this margin expansion journey </font></div><div style="margin-bottom:7.2pt;padding-left:90pt;padding-right:-9.35pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11.5pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:11.1pt">We reset our MA pricing and membership to improve underlying margins and are investing to improve member outcomes and support operational excellence, positioning the company for long-term success </font></div><div style="margin-bottom:7.2pt;padding-left:54pt;padding-right:-9.35pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">Further, we are advancing our CenterWell and Medicaid strategies which are expected to drive increased earnings contribution over the mid and longer term as they mature through their respective J curves </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Humana Inc. First Quarter 2025 Prepared Management Remarks</font><font style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">04&#47;30&#47;2025</font></div></div><div style="margin-bottom:7.2pt;padding-left:54pt;padding-right:-9.35pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">We have conviction that the strong core fundamentals and growth outlook for MA and value-based care remain intact and that Humana&#8217;s platform, unique focus on MA, and expanding CenterWell and Medicaid capabilities will allow us to compete effective, drive better outcomes for our members and patients, and deliver compelling shareholder value over the long term</font></div><div style="margin-bottom:7.2pt;padding-left:54pt;padding-right:-9.35pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">We look forward to further discussing our operations and outlook at our 2025 Investor Conference on Monday, June 16, 2025 </font></div><div style="margin-bottom:7.2pt;padding-right:-13.5pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:7.2pt;padding-right:-13.5pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:174%">Jim Rechtin, President and Chief Executive Officer</font></div><div style="margin-bottom:7.2pt;padding-right:-43.2pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:174%">Celeste Mellet, Chief Financial Officer</font></div><div style="margin-bottom:7.2pt;padding-right:-43.2pt;text-align:justify"><font style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">1 </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Centers for Medicare &#38; Medicaid Services, Monthly Contract and Enrollment Summary Report, December 2024</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>hum-20250430.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:e5e9e503-258c-45f1-8531-8025894f3404,g:1fbfcee5-b4be-4719-90c1-a5050312e034-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:hum="http://www.humana.com/20250430" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.humana.com/20250430">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hum-20250430_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hum-20250430_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.humana.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>hum-20250430_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:e5e9e503-258c-45f1-8531-8025894f3404,g:1fbfcee5-b4be-4719-90c1-a5050312e034-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SecurityExchangeName_c0eb0db2-8167-4dff-9978-fe68947166c5_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_e25d3e15-cbaa-4c70-93b7-fa600b499a1f_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_875944b7-c092-4381-8325-7b05571c73ec_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c4f4169e-caec-42aa-96a5-bdd4e6b2ac07_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_e6bf3a20-a4f7-41e4-b447-737d8de854f2_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f211dcf8-e43d-436e-8076-ba8943d0dd33_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_1b6b35ae-41ef-48d9-a129-fdeac2b94392_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_7e371849-abfd-4dcf-90f9-912cd1438bf1_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_23ec4d4c-ab9f-4767-b416-f73b4c580abd_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_5bbe2170-adf2-4feb-a427-21ebe92be084_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7920e281-1351-4b6a-96d5-94444ff7bba4_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_8d2607f6-acfc-447c-8fe3-08b0acf7a2dd_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_b42d2b1e-16d7-4da7-8af7-759a221c2a5f_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_0fefd893-6048-482b-a43c-5f57f5050bb8_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_31fa0082-6111-4100-b72d-980a046184b4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_c2af5485-5e09-4939-b055-adc9fb713374_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_2ad005be-8fef-4c48-9527-31652fe070d9_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b5130ff5-22b1-426a-b1bc-03106fb534d5_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_f21b9c5d-2af5-4510-9d63-4378a936398d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_46ee98c4-dced-4460-b8ec-6d604b214ea1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_21b6e963-e07f-4ad9-92e4-fe7f10da6a31_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_94f3a89b-bc40-4714-8ad9-cc5520222f14_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c81bfe92-9a62-4466-8cca-27197eba6378_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>hum-20250430_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:e5e9e503-258c-45f1-8531-8025894f3404,g:1fbfcee5-b4be-4719-90c1-a5050312e034-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.humana.com/role/CoverPage" xlink:type="simple" xlink:href="hum-20250430.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_f58db3ff-c4f6-4e59-bbf9-2889d30678c0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_3967eb67-d035-4c13-8591-96483a9c7253" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f58db3ff-c4f6-4e59-bbf9-2889d30678c0" xlink:to="loc_dei_DocumentType_3967eb67-d035-4c13-8591-96483a9c7253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_dde27d87-5ade-42fb-a5cd-d2177653ab47" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f58db3ff-c4f6-4e59-bbf9-2889d30678c0" xlink:to="loc_dei_DocumentPeriodEndDate_dde27d87-5ade-42fb-a5cd-d2177653ab47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_2da87969-e696-4026-87a9-b0df4be50c11" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f58db3ff-c4f6-4e59-bbf9-2889d30678c0" xlink:to="loc_dei_EntityRegistrantName_2da87969-e696-4026-87a9-b0df4be50c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_6ad8ed2e-e0dd-4303-8f24-916085eed999" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f58db3ff-c4f6-4e59-bbf9-2889d30678c0" xlink:to="loc_dei_EntityCentralIndexKey_6ad8ed2e-e0dd-4303-8f24-916085eed999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_94a3b736-9ffb-457a-9de9-1c8209878d6f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f58db3ff-c4f6-4e59-bbf9-2889d30678c0" xlink:to="loc_dei_AmendmentFlag_94a3b736-9ffb-457a-9de9-1c8209878d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_286b7293-b95a-48fa-a222-620cfd67ee1c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f58db3ff-c4f6-4e59-bbf9-2889d30678c0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_286b7293-b95a-48fa-a222-620cfd67ee1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_22ae6cc6-81de-470e-95a5-13bebc10caa0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f58db3ff-c4f6-4e59-bbf9-2889d30678c0" xlink:to="loc_dei_EntityFileNumber_22ae6cc6-81de-470e-95a5-13bebc10caa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6b7a802f-7cd2-4709-81b3-d82b85592f42" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f58db3ff-c4f6-4e59-bbf9-2889d30678c0" xlink:to="loc_dei_EntityTaxIdentificationNumber_6b7a802f-7cd2-4709-81b3-d82b85592f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_fa1feaa5-7d07-435c-9b03-f979fba07cf2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f58db3ff-c4f6-4e59-bbf9-2889d30678c0" xlink:to="loc_dei_EntityAddressAddressLine1_fa1feaa5-7d07-435c-9b03-f979fba07cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c571103e-d8be-464c-a676-17474a7e8b97" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f58db3ff-c4f6-4e59-bbf9-2889d30678c0" xlink:to="loc_dei_EntityAddressCityOrTown_c571103e-d8be-464c-a676-17474a7e8b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_ac131047-6379-430f-9ff2-02f6effafdbf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f58db3ff-c4f6-4e59-bbf9-2889d30678c0" xlink:to="loc_dei_EntityAddressStateOrProvince_ac131047-6379-430f-9ff2-02f6effafdbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_1d49db48-eac1-4d26-bbf1-715276ff51a6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f58db3ff-c4f6-4e59-bbf9-2889d30678c0" xlink:to="loc_dei_EntityAddressPostalZipCode_1d49db48-eac1-4d26-bbf1-715276ff51a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_b5c0f497-93e4-4664-8d42-ea2eee0ac0f4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f58db3ff-c4f6-4e59-bbf9-2889d30678c0" xlink:to="loc_dei_CityAreaCode_b5c0f497-93e4-4664-8d42-ea2eee0ac0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a1bcda77-4403-4249-bd3b-c2bfe20c2262" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f58db3ff-c4f6-4e59-bbf9-2889d30678c0" xlink:to="loc_dei_LocalPhoneNumber_a1bcda77-4403-4249-bd3b-c2bfe20c2262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_b757702b-7947-4b04-9879-efe66652f883" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f58db3ff-c4f6-4e59-bbf9-2889d30678c0" xlink:to="loc_dei_WrittenCommunications_b757702b-7947-4b04-9879-efe66652f883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_63d3b697-3d4f-4d51-8abb-2a7eadb21310" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f58db3ff-c4f6-4e59-bbf9-2889d30678c0" xlink:to="loc_dei_SolicitingMaterial_63d3b697-3d4f-4d51-8abb-2a7eadb21310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_99dfda5f-6c30-4963-9a11-18ddcea4b065" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f58db3ff-c4f6-4e59-bbf9-2889d30678c0" xlink:to="loc_dei_PreCommencementTenderOffer_99dfda5f-6c30-4963-9a11-18ddcea4b065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_77714874-62e0-4db5-85f1-8a5863f89a2b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f58db3ff-c4f6-4e59-bbf9-2889d30678c0" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_77714874-62e0-4db5-85f1-8a5863f89a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_18ff2ca2-bebc-41fd-a198-f54e27a2ae52" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f58db3ff-c4f6-4e59-bbf9-2889d30678c0" xlink:to="loc_dei_Security12bTitle_18ff2ca2-bebc-41fd-a198-f54e27a2ae52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f806d92c-4e75-474d-9c1a-e0e1c17c607d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f58db3ff-c4f6-4e59-bbf9-2889d30678c0" xlink:to="loc_dei_TradingSymbol_f806d92c-4e75-474d-9c1a-e0e1c17c607d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_560d70c8-64dc-41cc-9af2-35fa49563e9e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f58db3ff-c4f6-4e59-bbf9-2889d30678c0" xlink:to="loc_dei_SecurityExchangeName_560d70c8-64dc-41cc-9af2-35fa49563e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_913b444d-1c5e-405d-a409-c2b6e77917a6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f58db3ff-c4f6-4e59-bbf9-2889d30678c0" xlink:to="loc_dei_EntityEmergingGrowthCompany_913b444d-1c5e-405d-a409-c2b6e77917a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>humanalogoa05.jpg
<TEXT>
begin 644 humanalogoa05.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "D B$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS3$XZI.->5TB<OQ-2O)\[NCJJ***^\/;"BDI: "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBBD 4444 %%%%, HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH ^8_VW/\ D$^%_P#KXF_]!6ODVOK+]MS_ )!/A?\ Z^)O_05KY-K\
M5XE_Y&,_E^1\?F/^\,]B_91_Y+)8?]>TW_H-?=0[U\*_LH_\EDL,\?Z-/_Z#
M7W57V_"O^X_,]K+/X'S'444E?9GK%75/^0?<?]<V_D:_+Z;_ (^9/]X_SK]0
M=4_Y!]Q_US;^1K\OIO\ CYD_WC_.OS7C#_EU\_T/GLV^R-;I7Z3?#'_DGOAW
M_KRB_P#017YLMTK])OAC_P D]\/?]>47_H(K#A#^+4]",J^*1TV>.M)]*\Y_
M: \2:CX2^%^JZGI4YM;V)H0DJ@$@&10>#[$U\AK^T5X^[Z[)_P!\#_"OK,QS
MRAEM54JD6V>IB,;##R4)(_0(9SZFBOCWX%?'3Q?X@^)&EZ5J>H_;;*[+(R2*
M 1A2001]*^PQ7?EV84\QINK3T2-L/7CB(N41>HI...]'3 KB_B]XGN_!OPWU
MS6;$+]KMH08BPR 2P7./;.?PKOK5(T:<JDMD;RDH)R?0[3<.N:,U^?K?M%>/
MFR?[=D_[X '\JZSX3_''QGK_ ,1M TZ^UB2>TN+D))&5 R""<=/:ODZ7$^%J
MU(TU%ZZ'EQS*E*2BD?:V*2CTS7F?QH^-5K\(+73FFL9;ZYO_ #/)5" H*;<E
MB>WSBOJ:]>GAZ;JU7:*/4G.-.+E+8]-YI&8#^(5\2^(_VN?&&K,ZV$=MI<1'
MR[%W,/Q/7\JX/4OC-XTU1BT_B&\&3SY;[1^0KY*MQ5A(-JG%R/)GF=*.D5<_
M1(W$2]9%!^M/616Z,,5^:C^/O$<C%FUN])/)/GMU_.M'3_B[XQTR17@\07H(
M.0K2%A^1ZUR1XNHM^]!V,_[5AUB?HYD45\;>!/VO-<TBXCB\16Z:G:<!I8@%
MD'OZ'Z<5U'CS]LB"-3!X5LFF8J,W5V"J@D= O4_CBO:AQ%@)4G4<K-=.IUQQ
M]"4>:Y]0;@O4@#ZTSSXMV!(N?J*_/;7OCOXW\02,T^N3P(22$M_W8^G%8"_$
M#Q*DAD&N7P?));SVZGK7D5.+:"=HP;1RRS6FMHW/TJ##UI<]Z_/KP[^T#XW\
M-R(T>LRW4:D$QW6'!'ISS7TI\&_VEM-^($\>E:NBZ7K+#$?/[N;_ '2>_L?7
MBO5P/$.$QDE3^&7F=5''TJS2V9[I12;@>0>*6OJ3TAGIBES45Q,EO&TLCA$4
M99F. />OG+XH?M<66CW$VG>%H%U"="5:\DR(@1P=O][Z]*\[&8^A@8<]>5CG
MK5H45>;/I(MCDD"F>='G!=<_6OSWUWX]^.-?D9I=<GMT)X2W(0 >G'-8#?$/
MQ,T@D.NWQ<8^;SSVKY*IQ;0B[0@VCRY9K33LHGZ4!E[,*=GZ5^<%K\6/%]FP
M,7B&^&#G#2DC\C73:3^TSX\TMESJBW:+_#/&#_+FM*?%F%E\<&AQS2D]U8^^
M?>D_G7R/X?\ VS]2@VIK&C17"\9DMG*GWP#_ (U]9VEP+JWBF P)%# ?45]+
M@<RP^/3=!WL>E1Q%.O?D=R7-%<?\4?B):_##PK+K=W;27<:R+$(XB,EF.!UK
MYKU[]LK7KPLNF:5:V2<X:8EV_I@UEC<WPN ER5I:D5L52H.TV?8IXZFF-(J\
MEP/J:^ =4_:*\=ZKN#:T\"'^&% N/QZUS5U\3?%=YGSM?OW![&8@8SG%?.SX
MMP\7:$&S@EFM-;1/TB6XC;@2*3]13]V[H<BOS4C^('B2-PR:Y?*PZ'SF_P :
MZ#0OCUXWT&1&AUR>=5(REP0X(].:F'%M!M*<&D*.:TV]8GZ&4@-?-_PK_:TL
M]<NX-,\3P)I]Q(0JWD>?*)/0,#]W/KTKZ-AD6:-71@R,,@@]J^MP>/P^.AST
M)7/4I5H5ES09-112$@<FO2.@3I2=.X%>3?%K]H70_ACNLT_XF>LD<6L3#"<<
M%SV_G7S-XI_:<\;>))'$5ZNF0'($=JN#CW)YS7S6.S["8*7(WS2\CSZV-I47
M9N[/O S(O)<#\12K(C=&!_&OS9F^)'BF[R9=?OG.<\S$<T^'XF^*[?:8_$%^
MI48'[X]/3FO"_P!;J-_X;L<7]JP_E/TEX]12U^>^F_M">.]+VB/7)90#]V8!
MACGU_P ]*[G0OVQ?$]@RKJ-A::@@X)7*,?4\9KNH\48*HUSWB;PS*C+?0^SN
M3]*.V:XOX3_$2/XG>$H=:BM7L]\CQM&Q!Y4X)R*[3O7UM&K"M!5(/1GIPDIQ
M4H[#J***W+"BBB@ HHHH **** "BBB@ HHHH ^8_VW/^03X7_P"OB;_T%:^3
M:^LOVW/^03X7_P"OB;_T%:^3:_%>)?\ D8S^7Y'Q^8_[PST;]G[Q;8^"_BCI
MNH:C((K1E:!I"<!=X(!/L#C-??=IJ%O?0)+;SQS1.,JR,""/J*_+[T-:%OXB
MU6SA6*WU.\@B7@1QW#*H'H #BM<HSYY;3=*4;Q9>$QWU>+@U='Z<^<G]]?SH
M\Y/[X_.OS,_X2O7/^@QJ'_@5)_C1_P )7KG_ $&-0_\  J3_ !KZ#_6^'_/L
M[_[6A_*?I5J4R"PN1O'^K;^1K\P9O^/F3_>/\ZTV\5ZVP(;6-0.<];J0]>H/
M-97J2<GKSUKYC.LWCFCARQMRGF8S%K%6LK6!NE?I-\,?^2>^'O\ KRB_]!%?
MFRW2OTF^&/\ R3WP]_UY1?\ H(KV^$/XM3T.W*OBD<9^U-_R1?6O]^#_ -')
M7P6O?Z5]Z?M3_P#)%]:_WX/_ $<E?!:]_I7)Q9_OD?0QS3^,CTG]G3_DL7A\
M_P#31O\ T!J_00?=K\_/V=?^2Q>'_P#KHW_H#5^@?\-?1\)_[I+U/1RO^$_4
M4]J\S_:._P"2+^)O^N*?^C%KTP]J\S_:._Y(OXF_ZXI_Z,6OJ,?_ +I5]'^1
MZ=;^%+T9^?U=U\#_ /DK7A?_ *_%_D:X6NZ^!_\ R5KPO_U^+_(U^&8+_>J?
M^)'Q5'^+$_1$?=%?+/[<'W_!WTO/_:-?4P^Z*^6?VX/]9X-^EY_[1K]?X@_Y
M%M3Y?FCZO'_[M+^NI\M5>TG0]0UZY^SZ;93WL^!\D"%B >F<=/QJC7TG^Q0H
M;Q!XG! /^CP_^A/7Y)EN$6-Q,:#=DSY7#4E6JJ#TN>1CX)^.FA\T>&;\IV'E
MX/(SG'I7*ZMH>HZ#=&VU&RFLIQ_!-&5/X9ZCZ5^GNT>@_*O//C9\/K#QQX$U
M.*>",WEO"TUO-M&Y&4$@ ^^,?C7V^*X5ITZ3G1GJM3V:N5QC&\'JC\^..,C%
M&T4IRI((P1UXI\"AIHU(R"P'X$U^<*+<N4^?MK8T="\(ZUXFD$>E:9=7S9_Y
M8QE@#Z9Z5L:I\)?&6BVK7-YX=OX85 )?RB0/R[U]_P#@K1;#1?#>G6]A:Q6T
M/D1DK&H R5&3]?>MUHU92&4$8]*_2J/"=*5).=35H^BAE<7%.4M3\ML$,01@
M]P>#4EO<2V<\<\#M%+&P974X((.00?4$5[-^U7X%M/"/Q AO+"%;>UU6'SC&
M@PHD4X; Z '*GCN37BO/;K7P&+P\\%B)4F]8]3PJM-T*CAV/T(^!/CT_$3X=
MV%_,VZ]AS;W/^^O&?Q!!_&O1.Q]:^7OV)=2D:S\46))\N*2"8#W<.#_Z *^F
M[B98+>61CA54L2?:OVK*<2\1@85IO6WY'V&%J.I1C-GS!^UC\79[.9?!^E7#
M1$H'OI(SS@\B//;(Y/U KY8X/)'-;/C+Q!)XK\5:MJ\S%FO+EY1GLI/RC\!@
M?A6+SD #/I7Y!FF,J8[%2G)Z7LD?*8FLZU1NY8LK&YU*X2"TMY+F9C@1Q*6;
M\AS^-=9'\&?',R!T\,:BRL,C$7:OKK]GOX3V/@7P;97LUNCZU?1K-/,Z@LFX
M9" ]@ <'U.:]=VCC 'Y5];@>%8U:,:E>5FSU:.6*4%*H]S\X+[X4>,=.0O=>
M'-0BC4<DPD\8)SQ[ UR8]^:_4>YC5H9,@'Y3V]J_+C_&O#SS**>5\G)*_,<6
M-PL</;E=[BG')%?J!HW_ ""+,_\ 3)?Y5^7[=*_4#1?^039_]<E_E7N\'[U?
MD=N4_:/'_P!KS_DDDG_7Y#_,U\/\=.U?<'[7O_)(Y/\ K\A_F:^'Z\OBK_?E
MZ'-F?\=>A)!;37<RPV\4D\K=(XU+$_0#DUU%C\)_&.I1[[;PYJ$J'D'R2./Q
M^M=+^S2 WQFT($ C$AY_ZYM7WPJ+C[H_*C)<CIYE1=6I*UF/!X*.(ASR9^=-
M]\&?&VFQ-+/X;OA$HRS+'D <^GTKCKBWEM9GBGC:*53AD=2"/P-?J05'IQ]*
M^:?VOOAS9'P[;^*K2W2&]@F6&Y:-0!(C$@$XZD-CGWKLS/AF.&P\JU&5^7H:
MXC+E3@YP>Q\E],D=>V*^R?V2_B7-XF\.W/A^_F,MYIH!B9CEFA/0?@>/Q%?&
MU>N?LLZP^E_&'380Q"7L4MNP['"E@?P*_K7A9%BY87&P2>DM#BP-5TZL4GHS
M[OKS7X]?$Q?AGX(FN8&!U*Z/D6JG^\>K8] .?RKTL?KBOBG]K_Q,^J?$B'25
MDS!IELH*9X\R3YB<>ZE/RK]0SO&/!8.4XNS>A])C*WL:+DMSQ"^OKC5+R:[N
MY6GN)F+O(Y)+$GDDFH-I8@*"3V Y-!SVKZ._9+^%5GX@FN_%&JVZW,-K)Y%I
M%( 5+@99B.^,@#/O7Y!@<)4S'$JE%ZO=GR=&E+$5%%'C6E_"GQAK-L)[+P[?
MSQ-T98B!^M69O@WXXMU+R>&-05?7RB:_1:.%8U 50 .@ I^P-QMK] 7"-"RO
M-W/>65PMK(_+S4=-N])O'M+VWDMKF/&Z*12K#/()!JO7K/[4JA?C1K( POEP
M?^BEKR:OSC&4%A\1.BG\+/GZU-4ZC@GL?</[(O\ R2*WS_S]3_\ H=>U_P 5
M>*?LB_\ )([?_KZF_P#0J]K_ (J_;\H_W*EZ(^RPO\&/H.HHHKV#J"BBB@ H
MHHH **** "BBB@ HHHH ^8_VW/\ D$^%_P#KXF_]!6ODVOK+]MS_ )!/A?\
MZ^)O_05KY-K\5XE_Y&,_E^1\?F/^\,T?#_AS4?%.J)I^EVS7=VZEA&G/ Y)_
M 5U?_"B?'&/^0!<_D*Z;]E#_ )+)8 C/^C3_ /H-?= 48' _*O0R;(J.8X=U
MJDFG<Z,'@H5Z?/)V9^>/_"B?'/\ T+]Q^5'_  HGQS_T+]Q^5?HAM'I1M7TK
MW?\ 5+#?SL[?[+I]S\SO$G@G7?",B+J^FW%D'^ZTBD*?8'IFL2OTA^(_@VP\
M:^$-2TZ\@2020L8V8#*.!E2#V(.*_-YU"2,N3\I(_6OC<ZRE974BHRNF>1C,
M*L-)6=TP;I7Z3?#'_DGOA[_KRB_]!%?FRW2OTF^&/_)/?#W_ %Y1?^@BO>X0
M_BU/0[LJ^*1QG[4__)%]:_WX/_1R5\%KW^E?>G[4_P#R1?6O]^#_ -')7P6O
M?Z5R<6?[Y'T,<T_BH]*_9U_Y+%X?_P"NC?\ H#5^@?\ #7Y^_LZ?\EB\/X_Y
MZ-_Z U?H$/NU]'PG_NDO4]'*_P"$_44]J\S_ &CO^2+^)O\ KBG_ *,6O3#V
MKS/]H[_DB_B;_KBG_HQ:^HS#_=*O^%_D>G6_A2]&?G]7=? __DK7A?\ Z_%_
MD:X6NZ^!_P#R5KPO_P!?B_R-?AF"_P!ZI_XD?%4?XL3]$5_AKY8_;@_UG@[Z
M7G\X:^IU_AKY8_;@_P!9X.^EY_.&OU_B#_D6U/E^:/JL?_NTCY;KZ5_8H_Y&
M#Q-_U[0?^A/7S57TK^Q1_P C!XG_ .O:'_T)Z_,^'_\ D8T_ZZ'SN _WB)]<
MUGZXH;1[U3R#"X/XJ:T*H:U_R"+S_KB__H)K]KJ_PY>C/L9;,_,B^4+?7( P
M!(PQ^)J.V_X^(O\ >']*DO\ _C_NO^NK_P#H1J.V_P"/B+_>']*_GO\ Y?\
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MN7CMQ/\ A&RR']%-?GTO05S<61:Q<7T:,\T3]JF>E?LZL%^,7A[)Q^]8#/\
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M7XKQ!_R,:G]=#X_,/]XD?4'[$/\ Q^>+_P#=M/YS5]%_$*,R^!O$"(,LVGW
M ]_+:OG3]B'_ (^_&&?[MI_.:OJ6]MUN[6:&0;DD0HR^H(((K]$R*//E48KL
MSZ#!*^%2/R[]N]7_  _,EOX@TR5SA$NHF8^P8$FD\0:3+X?US4=,G!$MG</
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MY!%>E&I&;M%W.I23V):***V&%%%% !1110 4444 %%%% 'S'^VW_ ,@?PO\
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M_7 _X5YG$V'JU,:I0BVK'/F4)2K*RN=5^S/_ ,EFT/\ [:?^BVK[Z["OBO\
M9P^&OB6Q^*>G:A>Z1<V5G:I(SRW"%1RA  SU.3^E?:@Z"OIN%Z4Z>$DIJSN>
MCEL91HVDK"UY;^TO_P D8\0_[D?_ *-2O4J\[^/6@WOB3X4Z]8:? US>21J4
MB3DMAU) ]\ U]%F$7+"U(Q5VTSNQ";I22['Y[5Z%\ ?^2Q>&/^OEO_0&K%/P
MO\7=!X=U #_K@?\ "NY^"'P_\2Z7\5O#EU>:)>VUO%<%GEDB*JOR,,D^E?B^
M!PM>.+IMP>Z/D:-.:JQNNI]U@?+7B_[3OPSD\=>"UO+*$RZGIA,T:J/F9"/G
M4>IP 1[BO:/X1364,I4C((Z5^UXK#1Q="5&>S1]C5IJK!PEU/RUVE6(8$$'!
M&,&I;>XEM9DF@E:*6,Y5T)# CN".AKZZ^,?[*\'B:[GU?PP\=C?R9:6S?B*1
MLYR"/ND]^QXZ=:^;O$'PE\7>&YGCO="NT"G'F1QEU/T(S7XQC,IQ>!J/W79;
M-'Q];"5:,MMCH]'_ &E/'VCVZP#6!=HH !NHU=L>N2,_G63XG^.7C7Q=;M;7
M^MS+;.,-';@1*P/8A<9Q7,6WA;6;R810:5>22GHH@;/ZBO7_ (;_ +*?B'Q-
M<0W.O*=&TW.60X,S#N .@SZGIZ&M:']J8NU*#DTRX?6:ONIL\,Y9B2<G/4G/
M7G-%>T?'+X*ZMHGCAX?#V@W$NC?9X5@:WC+CA0&R1_$6!)SUSGO7G_\ PK#Q
M;_T+NH?]^#_A7G5\!B:-65.4&VNISSH5(R::;/KC]D7_ ))';GH/M4__ *%6
MY\9-2OKNZ\->$]/N9+-O$%T\4]Q&<.L$:%Y #V+*",U0_9=T:_T'X6P6NHVL
MME<"YF8QS*5;!;(.#6[\6?">HZO!I&M:(JR:WH=S]JMX7.!,I&V2,GMN4D9K
M]=P].:RN$4M;*Z_,^KIQDL/%'A6I:];^']3UG1K2RT2XMK/418Q:-);%KBX0
MD MN')/).3Z&O7OA@\_A'QWKG@HRR3Z9#;QZEIWF,6:&)V*M'D]@P./:O.;Y
M/#UR+V^D_M33O%$FI_VG!'_9S--!(  8\@893@CDC(]*]4^&/A_5+S7M7\8Z
MY;_8KW4DCM[:R/+6]NF<!O\ :8DL1VS^ X,!3FJZMW_#4QHQDIH]-HHHK[,]
M4**** "BBB@ HHHH **** &LH/49I/+7T'Y4^BIY4]T T*%[#\!3J**:26P!
M1113 *9Y:_W1^5/HI-)[@,\I?0?E3AQQ2T4DDM@"BBBJ :?0C-0O:Q2?>C0_
M4"IQ142BGNA6ON5UL8.#Y,>?]T5*L:1C 0#Z 4^EI<D5JD%D)C'04M%%:#"F
ME0W4 _A3J*32>X#/+7^Z/RI54+T&*=1244MD 44450#/+'7 _*CRUZX'Y4^B
MIY5V%8****H8QD#=<'ZT>6OH/RI]%3RKL(:%"]!C\*=11322V&%)2T4P(9+:
M*3[\:L?< T1V\4?W(U7Z "I,BC(K/DC>]A60OX4WRU_NC\J?15M)[C(_+']T
M?E4E(,TM))+8!K*&[<4GE+Z#\J?11RI[H0U5"]A^ IU%%"26PPI,9]Q2T50#
M/+7T'Y4",#D #\*?14\J["L%%%%4,*C>))."H8>A IX-+4M)Z- 5ELX8SE8E
M!]0HJ?;CH,4M%*,8K96$DD-:,-R1GZT>4O7 _*GT4<JOL W:%X P*6EHJK#(
M/L\3/N,:EO4@9J; ]*.E+4J*6J5A!1115C"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>humanalogoa051.jpg
<TEXT>
begin 644 humanalogoa051.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "D B$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS3$XZI.->5TB<OQ-2O)\[NCJJ***^\/;"BDI: "BBB@ HHHH **** "BBB@
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MHHH **** "BBB@ HHHH ^8_VW/\ D$^%_P#KXF_]!6ODVOK+]MS_ )!/A?\
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M!(PQ^)J.V_X^(O\ >']*DO\ _C_NO^NK_P#H1J.V_P"/B+_>']*_GO\ Y?\
MS_4^"7QGZ;^'?^0#I_\ U[Q_^@BM'_"L[P[_ ,@'3_\ KWC_ /016C_A7]!T
M?X<?1'WD/A1\H?MN?\A+PF?^F=S_ #CKYBKZ<_;<_P"0GX2_ZYW7\XJ^8Z_%
MN(/^1A4_KH?'YA_O$CZ@_8A_X_/%_P#NVG\YJ^C/'TSV_@?7Y4.UTL)V4^A$
M;$?K7SG^Q#_Q^>+_ /<M/YS5]%?$4_\ % ^(?^P?<?\ HMJ_0<D_Y%"]&>_@
M_P#=4?FKTX[U>T&W6ZU[3H'&4EN(T;Z%@#^AJCW-:?AC_D9M)_Z^X?\ T,5^
M2T]:Z3[_ *GRL?C7J?IE8QB&TAC7HJJ!^ JQZU%;\0I]*E]:_H2GI!(^\CLB
M&Y_U$GT-?ENO45^I%S_J)/H:_+=>HK\YXP_Y<_/]#P,V^Q_785NE?J!HO_()
ML_\ KDO\J_+]NE?J!HO_ "";/_KDO\J7!^]7Y"RG[7R/'_VO?^21R?\ 7Y#_
M #-?#]?<'[7O_)(Y/^OR'^9KX?KR^*O]^7^$YLS_ (Z]#U+]F?\ Y+-H7_;7
M_P!%M7WV.E? G[,__)9M"_[:_P#HMJ^^UZ5]1PG_ +G+U_R/4RS^"PKRK]IR
M%9O@OKZL.%$+#ZB9"/Y5ZK7EW[3'_)%_$7^Y'_Z-2OI<RUP=6_9G=B/X4O0^
M Z]"_9_)'QB\+E3@_:#^1C8&O/:]"_9__P"2Q>%_^OEO_0&K\0R__>Z?JCXS
M#_Q8^I^A7\/O7Y[?M!SO<_&7Q.[\L+A$]>%C51^@%?H1_#G/&*_/+X]_\EB\
M4?\ 7U_[(M?H_%E_JD/4^CS3^$D<"W2OO+]EZQ2S^#VD;0 9FDE;ZES_ $%?
M!I[U]^?LT_\ )'= _P!QO_0C7SW"D4\9)]D>?E?\5GJ5)2TE?KA]2?!?[4W_
M "6C6O\ KG!_Z*6O)J]9_:F_Y+1K7_7.#_T4M>35^!9K_OU7U9\/BOX\O4^X
M?V1?^21V_P#U]3?^A5[7_%7BG[(O_)([?_KZF_\ 0J]K_BK]ERC_ '*EZ(^N
MPO\ !CZ#J***]@Z@HHHH **** "BBB@ HHHH **** /F/]MS_D$^%_\ KXF_
M]!6ODVOK+]MS_D$^%_\ KXF_] 6ODVOQ7B1?\*,_E^1\?F/^\,]B_91_Y+)8
M?]>TW_H-?=0KX5_91_Y+)8?]>T__ *#7W57VW"O^X_,]K+/X'S'4445]H>L5
M-4_Y!]Q_US;^1K\OIO\ CYD_WC_.OU!U3_D'W'_7-OY&OR^F_P"/F3_>/\Z_
M->,/^77S_0^>S;[(UNE?I-\,?^2>^'O^O*+_ -!%?FRW2OTF^&/_ "3WP]_U
MY1?^@BL.$/XM3T(RKXI'%_M3?\D7UK_?@_\ 1R5\&#O7Z"_M$:2^L?!WQ-#&
MN7CMQ/\ A&RR']%-?GTO05S<61:Q<7T:,\T3]JF>E?LZL%^,7A[)Q^]8#/\
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M7XKQ!_R,:G]=#X_,/]XD?4'[$/\ Q^>+_P#=M/YS5]%_$*,R^!O$"(,LVGW
M ]_+:OG3]B'_ (^_&&?[MI_.:OJ6]MUN[6:&0;DD0HR^H(((K]$R*//E48KL
MSZ#!*^%2/R[]N]7_  _,EOX@TR5SA$NHF8^P8$FD\0:3+X?US4=,G!$MG</
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MY!%>E&I&;M%W.I23V):***V&%%%% !1110 4444 %%%% 'S'^VW_ ,@?PO\
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M_7 _X5YG$V'JU,:I0BVK'/F4)2K*RN=5^S/_ ,EFT/\ [:?^BVK[Z["OBO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
M_]C_X  02D9)1@ ! @$!] 'T  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" %U!-4# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "C
M(]:*A)\O+[L^U)NP:W)J*J&ZCV[GG52>Q;%+_:5J3C[2G_?8K.I6IT[79*DK
MZEDL .M <'KQ59[^U'W;B,_\#%'VZUVY^TQ]/[XI>WAT8<T;VN6LCU%&1ZU4
M%W#)C%Q'^#BI-P#>8I/(QBKYW96*33V)Z*C))ZFBK$FFKDE%(IR!2T#6H444
M4 %%(_W>M,<'D TKZ@249'J*9OP,,>@JN;R#'$RCUW, :AU%'<&TMRWD>HHJ
MH+VU'(NH_P#OL4+>VPP/M*$?[XJ56A;5D.:+=%5_[0MO^?A/^^Q2/?1.A\J9
M2>P#4XUJ;6Y3:3L6:*ACD\U0[$CM3@6#C!X-:)MC)****8!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML#[E-7!#D4Z@# HIK5#"BBBF V0 CFF!0.E2,,C%-*%14M1OJ)J^IQ7QY/\
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M>/0TKJ]ABT44A< XHN@%HI-XI00>AI@%%)NP<&@L!WH"XM%-#^HI2P'>DFF
MM%-9^.,T!L#DTP'44A<=J9YV/>DW8:5R2BF[SZ4X'(S36JN*^M@HHHH ***0
MD 9-#=D M%)O6@.#2335P%HI-ZTH(/2DIQ86"BBDW*>]5<!:*,@]#12YD 44
MA.!D4F\^@I[@.HINY_[OZ4I8 XH%="T4TN.PI00>E2Y)#%HI"P7K06P,BG=7
M 6BF[SZ"@.<]*8FTAU%(S;3C%"ODXQ0',KV%HI"X% <&CI<+J]A:*,CUHR#T
M-)23&%%%(S@<4P%HIOF'T%.H ***,@=32<D@"BDW+ZT;ESC-.X"T4A< XHW
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MJ>K/R_-_]ZEZB4J]1]:2E7J/K7R<CS:>S'0_\?*?]=!_.OU\_8#_ .2$6/\
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M^,^];2;2YKE:VN/('8TH( Y;-1">$C(E7\Z#-'CB0?G252.S:%>ZO<>3DT$
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M4WHBK*PE'2@\\XI'SCBK2;=Q)*3%SGO2-N XI8B,X].M(S@\C!IR:V&[1=[
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ML<&GT@ W9!I:I;!>X4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?>GQ?ZK\*_F26[1^;R]UJPUA@@COUK7\!*&\6VF>TZX_,5D.0,9]:V/ ./\
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M'05)MS^%)*0BAS^(J.;W_0Q;;1TOPG^)&M?#3Q);Z_H]\\(24%]AZ@&OU?\
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M#::M VQH9@PQ[5^PG[&OCU_''P=TB_EFWN+1=Q)SW-?C2SJ6* X)'!K],/\
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MM3?^6E2/U_"OPQ12U/BV]!M?3_\ P2G_ .2ZW_\ UXI_Z$:^8*^G_P#@E/\
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M +![?S%?C!XF_P"1AO?^OAJ_"O%/_>:?H?'\2_&O0HT445^-=SXN.["ON/\
MX)'_ /(0N?K)_(U\.5]Q_P#!(_\ Y"%S]9/Y&OM.!O\ D;1/=R7_ 'V/H?H;
M:_ZO\!3_ ./\*9:_ZO\  4_^/\*_J*G_  T?HT!).U?EG_P5P_Y.6_[A$'\J
M_4R3M7Y:?\%;O^3EQ_V"8/Y5^>^(W_(D?J>+Q#_R+_F?*Z?=%.[?C34^Z*=V
M_&OYID?F]02NF^$'_)5]"_["$=<S73?"#_DJ^A?]A".O5R7_ 'VGZHZ<-_%A
MZH_:?X4?\B+IO_7J/YFNE3K^%<U\*/\ D1=-_P"O4?S-=*G7\*_KC+O]RCZ(
M_5J'\&/H.IH8F0KV IU(W4'WKN>QLB&;)1@WK7PG_P %8(RVG6I])6_]!K[M
MN.A^M?"O_!5[_D&6_P#UT;_T&OB>.?\ D43/'SG_ '*1^?:,&)0CG-%(H&.E
M.;[QK^7JO\1GYK/XQ!]__@-6=#_Y",/^]58??_X#5G0_^0C#_O5TX#_>X>I=
M#^(?L)^Q5_R1W3_^N$?_ *#7L@^Z:\;_ &*?^2/:?_UP3_T&O9!]TU_6F0_\
MBRGZ(_5<#_ND?0/X/QH3[PH_@_&A/O"O8ZHZOL"CJ?H:^9O^"G'_ ";EK'_7
M#^IKZ9'4_0U\S_\ !3O_ )-KUH_],?ZFOGN*_P#D3U/0\_,?]SGZ'Y1QD!<G
MUIU,'W/^!4^OY-Q?\1GY:_C"BBD4\GZU-+XD**O-'ZC?\$FA_P 8UVW_ &$+
MC^8KZK0@+^%?*G_!)K_DVJV_["-Q_,5]6Q=/PK^L>#]<BI>A^HY9_ND/08Z@
M(8_3I7Y_?\%@45M2TG/461_]#K] Y\>6?6OS_P#^"OF#J6DG_IS/_H=>?QO?
M^R)^A.;_ .Z2/@X #@44@^^?I2U_+LG[S/S%JU0;C<01WJUX=3'B"R)Z?;(_
M_0A5:7HI^M7M P-;L2?^?N/_ -#%=> 5\9'U-*&M5'['?LD;6^#^EE1C,7]!
M7JJG+;*\K_9(_P"2/Z5_UR_PKU9.E?UEP\K9;3]#]1P'^[1] C[TZFIWIU>W
M]H['N%-?K^%.IK]?PI2W!E#Q/_R"+C_KD?Y5^&_Q2_Y*;X@_[#5S_P"C6K]R
M/$__ ""+C_KD?Y5^''Q1Q_PLWQ!_V&KG_P!&M7XMXI_PJ9\CQ3\$#!_Y:5(_
M7\*C_P"6E22<M^%?AWV3XKHAM?3_ /P2G_Y+K?\ _7BG_H1KY@KZ?_X)3_\
M)=;_ /Z\4_\ 0C7U/"/_ "/*7J>MDW^]P/U.@_U0J9/NBH8/]4*F3[HK^KZ/
M\-'Z6OA&2_<;ZU^:_P#P5J_Y'RW_ .NB_P#H)K]*)?N-]:_-?_@K5_R/EO\
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M(_"C]"MJ%%%%4,*CNO\ 4M_NFI*CNO\ 4M_NFLJW\)B>Q^2G_!23_DXO6/\
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M1>@^E*WWC7\O5?XC/S66LV(/O_\  :LZ'_R$8?\ >JL/O_\  :LZ)_R$H?\
M>KIP'^]Q]2Z'\0_83]BG_DCVG_\ 7!/_ $&O9!]TUXW^Q3_R1[3_ /K@G_H-
M>R#[IK^M,A_Y%E/T/U7 _P"Z1] _@_&A/O"C^#\:$^\*]CJCJ^P*.I^AKYG_
M ."G?_)M>M?]<?ZFOI@=3]#7S1_P4\ '[-FM#_IB/YU\]Q7_ ,B>IZ'GYBKX
M.?H?E"/N?\"I],'W/^!4^OY.Q?\ $9^6OXPH Q10?ND@\UG33<D$-9'ZB_\
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M#]X4OM".+^.QV_"[6R?^@;-_Z :_%/QB0?$UV1_STK]K/CUS\+]:'_4.F_\
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M4O42E7J/K24J]1]:^3D>;3V8Z'_CY3_KH/YU^OG[ ?\ R0>Q_P!]OY"OR$B
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M_K3(O^193]#]5P/^Z1] _@_&A/O"C^#\:$^\*]CJCJ^P*.I^AKYI_P""GO\
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MHDXK5BCL/ZT4T2*>,')[4K/M .T\TDXRV&+13?,]J<#D9JDK %%%%, HHHH
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M\HV7[C?6OS7_ ."M7_(^6_\ UT7_ -!-?I/+]QJ_-?\ X*UD#QY;DG_EHO\
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M &@/VO/ /PLT:9TUN"2Y52!"LGS9KR\PS+#8:A*4YI:=S&KB*-.+YI'Y]?\
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M!-?!>(&F4RU/'SSF>"9\<@X I:11\HI:_F1M-L_.9I\]V)@9S5[PS_R'K?\
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MJ4'#2,CS9JK.>A:TC7M4T&_2^TN\>-U.00V*]W^%7_!0#XJ^"$CM+S4'GBB
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MV2?A3W\.VWU\E:]6VC^^*0@#HU8+(,N<K^S0+!89?9/.M"_9I^&GA^\6^L=
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M'^&$"NV;<!UH3H:[Z.1Y=0^&"-E@\.E;E,K3_!VAV"@6^G1*/9!6C#86L/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "DVC.<TM%)M@(R[J%7 Y I:*2;
M,#T%-921\H%.HJ@$5<4%03FEHH **** "BBB@ HHHH ****  \C%(J!>]+10
M $ C!H P,444M "C'.?2BBC0!&7)S1MY! I:*8!1110 4444 -=23D4FQJ?1
M4N:0#0A'IFEVY'('X4M(Q('%*[EL FQ1W-(,9]J 23@DTX*!R!1R6W8-"D>E
M,P1D[N_K3Z0JI[4<@#23TS2ITQ04(Z<TJ @<BJ2L-M6%HHHIB"BBB@ HHHH
M#GMBDQG[P%+10 8'I1@>@HHH 0J#VH  Z4M%3<!&!/0TM%%";8!1115 %!&>
M]%% "; >I- 0 YI:*FX!1111< HHHJ@"BBB@ HP#U%%%)L P/048'H***5P#
M ]!1@=Q1133N 4  <CO113 ****FVH!1115 %%%% "%@#@TA 8?**5MF>:
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M, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+"BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 30,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Humana Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000049071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-5975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">61-0647538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">500 West Main Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Louisville<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">KY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">40202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">580-1000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HUM<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( +DPGEI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( +DPGEK +14Q[@   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DL].PS ,AU\%Y=XZ;2F'J,MEB!-(2$P"<8L2
M;XMH_B@Q:O?VM&7KA. !.,;^Y?-GR9V.0H>$SRE$3&0QWXRN]UGHN&%'HB@
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MM5II ,,X?<D3$L/<@HL(2W@4R]9<X%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A
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M*L,,CL%Y99_D/H;ZB;F(BJPA< V27=H*NNU>YZR/$>Y9.CV&\#*.P0/-R>Z
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MTG1X#SY['R73>RHY_U=3_ 102P,$%     @ N3">6I>*NQS     $P(   L
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M<F]P<R]A<' N>&UL4$L! A0#%     @ N3">6L M%3'N    *P(  !$
M         ( !PP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ N3">
M6IE<G",0!@  G"<  !,              ( !X $  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " "Y,)Y:@/Y3MBD$  !9$   &
M@($A"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ N3">
M6I^@&_"Q @  X@P   T              ( !@ P  'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " "Y,)Y:EXJ[',     3 @  "P              @ %<#P
M7W)E;',O+G)E;'-02P$"% ,4    " "Y,)Y:&445]3<!   G @  #P
M        @ %%$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ N3">6B0>
MFZ*M    ^ $  !H              ( !J1$  'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ N3">6F60>9(9 0  SP,  !,
M     ( !CA(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @
&V!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="hum-20250430.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="hum-20250430.htm">hum-20250430.htm</File>
    <File>hum-20250430.xsd</File>
    <File>hum-20250430_lab.xml</File>
    <File>hum-20250430_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "hum-20250430.htm": {
   "nsprefix": "hum",
   "nsuri": "http://www.humana.com/20250430",
   "dts": {
    "inline": {
     "local": [
      "hum-20250430.htm"
     ]
    },
    "schema": {
     "local": [
      "hum-20250430.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "hum-20250430_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "hum-20250430_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.humana.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20250430.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20250430.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0000049071-25-000021-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000049071-25-000021-xbrl.zip
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M-^"E&&;*FL+Q32TG=RHG_^5Q"K#2UP*2[$)HXK:G?M08.0?%"[8#RT"PGD
MAK*RG$ 9YBJ]@25'4JLT\4 ^9D 8"<(&/_J$1XCM7+PG8V38LH&PC(R .23A
MC84>B=T4.>/3[!_X1,=&G^"8Z+T$E\RU#F9J>-;<;YTLP(WK<3 EJ7^GLQ,#
MS8A4(@#$>( 8$:"<E*4HI4RM%$/;; #G-/\ H0.$;S". =B0V*(HYG!,!GL@
MIL8 FRBI]="6]=!GAX)4S0J.E;XM 14N*I7E#MAKJ&(93!)^BS8W!B%42L'D
MF0C[#%_0F5IEA,F"^:V!DH'+C;FJ+-<]XIG,,5BMK79KU5.!H\,S(1*#DT:%
M#VA\.%"-1(9-HB1F*H6VN4I?'&GK.6QNK$#? *9QW>=XC9_S5+#.48/--U6N
MC^?TK31J=U=KU*Z;KNNFZV=18K^AINMIM7#<ZBY2 XNA(#9'_1)%=.E^9?NZ
M[SS@UCL+3D7P)\OG7Q[UNE-:[Y&6T%.]_X<OEW:NM!0/V(E++,X3F01+8<T^
ME5&P'-#MM%FPWSJEA>C\&Z03U6F[WB?VZC^_O7M=+<T.14"%+RIBTST1!P='
M%)20YN'N8$)@N[=<+2HJQ5^]_\]K*R[OO>6ABX.XQUN=@4[;VV&@)1R-)7EG
MTZ[&*ES3:77PY3^6S($!?=@A<SW&+L452.-@]L0=J'#?"9FG0%3P$\B51) N
MZSU8:#+$(W.13BH8P6S+-!,<33'!TGAO"]C@GC3HBGPPM?Y?3H,N2?AG0/=N
MZ[B(=B*Y2FI-B+"&#?@( TY >[!S,L+4A-T;&9$A,Z3PC^$8L01Z@E: TU[U
MJ0J(OFVP&+W.$1CEA%["T.N0J2NOPWN!BY)1$.)UI9R!O$\M CXD$,9Y^=3>
M*[!(':L4' 4/12]BGUZF"'Y-=1UE$);XLI8P.Y$PGP6[KZW!5_2[7-'$U8[!
MUPJQ2/\4%(8DO[844Q6 <-L$4*GO:E2J<D<\!A5%,UB6K^^J[9,GMD\THE0#
M7;YD:%A(]VE;P_[N.$<D,D_8A-(Q\%NO  K'."?#(DK01Z'LHTSPB)&%?=+P
MV@V? ?4=B3J4)#RU=?343AY*C3<T><_($#2B?0P++!Y9H%)P_<+<8HY?P*&O
M/GRZ>%WSVLYY[3/AR6!/*8D>@R"(\<2SB&6!*L1\ 6M9V,XF[_<%@LS[- LR
MY*>[*5P=BQ/Z !>OS@G'C_>0'],I]-6[I#]JE0]!M6]ZK^TN%/W5[C62Z^!I
M5I5TORB4G+;CNL=+N9D/2/_*3:S8]T%CN#K*9.M_4J:=_D+9__X_#\>P:[F\
M+5[QVQ8YP&'NS+<[E-@MQ!S>9"#G80&ZF0,VFVOLV9PPKLF_(?)?&(L\7,P8
MBQ36X%=;M0Y*O&(L'6.O@*;O14_GZ$SB+@:WL>"B 0]]KR^./,$&E*(1#-.6
M#>0L7V'5*,1):+U$&Y^RTB7)XTPV26)XKR28!/'2Z>^::Y[0F"L\2.KPL=QC
M6SR13@4W6(I@PAJ^Z:/@2,48A041TH[0H/H9F^O.M49?5 N9]')M;"8G1F'B
M0UB%C&F4N?=JO1<F7H&(,@*9E&9H7[J^TRJ<6/DT3>0_C6&3![&)5DD5+4G;
M32>+EKRMJVAT9043M33&W4;,U&_*+K[)</[31:Q "UZC3_N.O;I^=[VL3[J-
MYN2_O+QZC$'<.3A<:!%7#9?O7AZ>GL^:PY7$BS-OE[*_VQ1OK[EAJ]H+XP1!
MK Q2(%&@.A05Z\"^G-(4?0I)V7E;H%4R'!6#TQ(_73 [C8F"WC$I*K22!\ T
M9+&@7,73A@J+U['NW/7G@IYT$ @],> CJ?2JE*<0>!WM_F*T&VE:V8>)O&M@
MU,B;$=:'F:+(EZ-(WA]Z/DKS6ZG>FB]2JJNWZNJMNGKKZ[:1??O9FJY];0<]
MG57<IG(DZK<^V6L\W$W=>-!X;BPH:,'G<VA/E8?A<:Q<+RM<[9] PSRX77;\
M2LTD&V&2R\4>3LDGG6/K+V'X;KJ K!KI;S 0\W8&,H67RZ3N EX[VBL2Q-::
MMO&A1(9#)7$^]7252C5079CCO#IU^O\D<@9G/MQ#DUAUQ5ZO>6J;/'7E4K_4
MJ8X]+"ZUNS"9\(0IW9IV*SG/]P0]$A4B#2L0G[ZJJ,0D=BB@J8. ,U7!3\-_
M30&Z581I<0/_C,'AD<TX:3H,V<).$@YGX\@\R#$63(%CE !>')%3;KLR@7W
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M S09Q2W3 E"(@$8#?AVV/* H$P!1TG[ B@']2  BFA<% 8T3UBH^[!>BEFD
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M5@X7@CEP&:>7*>KDR,^4'7CN"&.Z.B39M3JO>H>N'(LI'M8(AGYF@OG"&7:
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M5*?+^7(*/PTFQ*,IED"HDYS\#F28IL]( IL&#5%VW6>?#6DPP"0T E*V(N^
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M..HX;%DP7;/]_=DJ.L-^O]>S/U!+ P04    " "Y,)Y:PT 5JR *  !]50
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M@Q\9J48C*'2 \-_XWX.MNCM3C\6PY\G'HAM+KNZ\8'IJ8Q1(C\$FA^BIC3Z
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MDS>JO?LYC=W1.[HC]7+_#UV<6__V/)W;1;'(1%89U'\W:],R8XLY)UABCA1
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M]1//C7*M-<K=!S8'P!1=^;X34VTS0OQ-N,+GZ-9=6Y:8(J+ 'Q1U=D?LDP^
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M%2\5U43),WL/W]WE$?5+^[5ASVBW<PS23K5^CSWZ$/PKANM_PB!UPJ5,116
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M?K?&W!T)=N--)E(?R O&4N$9*B02N^ S8  JNX.YSN?S*L!L=>3-<"Z>FTD
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M(_@&WE"IB,F =(),R0FR?.A2'!0OG$P= @1F 3DH[))HOH%7H!8"M 1)&H@
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M;D^_[:14FMWIMU<UX O\;#_2\"OY0E_@+2L<X"RJPFT03I$=,_AI,DE\@+5
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MSR6A$SB[.'J]Q'\.FNN_\YE+E-)_W!$E!U,QY87>]M40%Q?9^,R>F)^ ]G,
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MS$@XF_V8JN4@K%@(=L"0/3$OF*(B7E<_#C^D\_EQ%H3:MMZ<S0#>EKGLZ^E
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M;DY=OH7FBI-GBQ%U'F^CG?*H<]H9EQ:K4=/-:GMT%::;[3U0K-JT!&G84]4
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M"KD.]$5)"<<5T9>6F70WT^,SA?LL24?7))^@C-K^HP_W#X7WBT;CG,$QLPQ
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MCLO3^>MTGDZ289\#1.CZ"8=XR)Y<5$L7#C:30"D<B>AP"IL$7%P"-M=?YQ0
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MZ4_N$'.Q86NN*"B:)51JN%^79R'.,KIYVJ^/]3=I_30J5T+;CHD'6 @ZQV_
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M'$R]G0VN4$IO/9GX]Y;>6G(D](_A2#@F\10[-NM.65-LYB*"S$,QP.88-'5
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MMVGW8EH_7)E&3Q'TCO49AJK.D)B@YRIX007FI764[ZJNK;*>F"KU; :7"=F
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MT3:T;F?'V="*JI545%)1244)#L@VM=Z&3G&JW+^65RK *L#6Z\KZ:,AE8WY
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MO]/'LJKII5\KLEKZW:YF54-6'8>G9G=_9]IV+P?;KF/U$%)IBM&!21V_,V\
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MZ[5LZ$<6..5158A-U]DC-G Z0VE4 *SK 0$LTU+Y2W I -9N@,6=8YU'K2D
M5@U9*RW;E T!L 3 VE1"1R9?X5%5"(#53,F;?^(@(Z,I3H@G$IGIDJFH_"5.
M%9$0M7-Z/!PF#PO)]229FB[9NE5[3OMSJ(Q!8,">2-6X[N :7M53Y]'C,5E$
M^("5+/O^<)QUEFH(9UW'N*;K/6/8L" >CX)6ZJQ357%_73CKMA:#%\XZ;N!6
M=RH05+I%M=^ YQ/8B!/LN=>'[YM.NWG2AO=OF%+"[RVIIB5D6+BR#B+S(MGG
MNV'5NI8:!([MORR>>CNK%[JP(\#Y?U(,!%[>E%_)*S#'\;T?+GF1+[9F"*51
M0OUQFYTN%9PS#V;W7;#Y\UTPY(=ND'DD:19DL#$BRW$D$#+$$^&N*<D^PFKS
MZ2HN2JRAOQ/BH=L FD47UZ/)WV_?+6F(<(*B.[2>D%U"&(4$= %Q8X(30I]0
M-9U.5D)1C%0=+4A,$VU+Z"Z.YLC1-$D#2FQIS(#&0@_4RF,([]F24K31 L-4
M<SELGCBV)*%N,6'*27A-W#QY^)**\GJ"C16UL2SL,8;>%E'BLVN5,0EPZC^0
MRT??2V>%*EQ]J] RRLLK> KZ/4O+7]G(L5Z7?E+52H2:C)QU(JS^I./TO3^]
M\1U%P99F31W;,@U+LZ<.T;%NV\H4_H0-\F]5=]XLWYH]ET=9@%X934':?QWA
M.YC;>QP\XJ=DG0)S4,_%D$P#QOR:4CD]?J39WK>-=-<3!XS?,-]LM'@Z#XQ*
M//B2S7&(T=?0E='&!)H=RFU,YGXV3YAZF9#XP7=)@KZ3!Q)F!!90BOT 7?P<
MXLSS4^*].]MPE>5P64OO_10>=ZNHZB@(,&A@/T303P!K,)$0^=TE@*= 3Q4:
M.O\(C<W>_F ZE\\&#SZ F";DGE;E1G$^[623*;O0!4,BKS:$+AW5(B'OEQ\N
METC&#]D<V$N7Z\V9B\VS4JHM\J^+=3+69$NQZ5(I?(=%Q\4JDMDJ>@5<\^\,
M0W94O?1K159+O]O5K*K+BNKPU.SN[\9Z>:='#U:5==,^2[/C:O,\4\*NUKU-
MSW,95YE+$U5+G$K.HT]1G$\HG9'EAY@4'YDB2O+/)/2(5\Q]M;Y)A0W77I_"
MN,1[NGL;RB=!;TE!T#R%1?YY\?S'7+73CQ=?WU%"'L. [<3?7@).53FJ ==,
M(;D-<:K:7^^54Q6'\$Y7$ ?+L&(&YU,KC7$XTY)[X]7J2QVQP#B9]DD,YFPN
M%5E8HLJ-<Y>OK;SVN>FE#N-3EQ&KR:XP][HE6^9^$U-CB.J&6V;[LOL:)EF,
M0[<\8.)0Y7JR*)U'6DY]] B>JTZC''^-9[?KIH.B9@ZVJEL/VLX/IJI!^?^J
M$'+:]#%8M9%KFC2VZXVMKB8M3<165SSE[([T;2=EF?15"^!L62Q+<(XF&8;-
M6TQOF:;?MMKY$)B^J2L5Q*+>O'C=T58<BM=@])$JZ2W50NL51/P,!%J<%%-]
MK*WF1H-IDJYI/=5@1P3?=8B?99K!L;E+Q7A I"Z/E"ZS_;I1;T:);JX<'CE6
MMC8TI9UT2;VRFL_V,DDQ$ H'44C0[?7M@*PFQ?WU7BGJYMKO'C^WT]766D33
M [*96LW7K+JY:GCD5XG%5,W>V<LVZ#A)<5IDW(.IA&F,W32/"(UHZA1T\?&T
M7,>\:MO2E'MC83W[8STU25>%_6QBY5A*O97"N5XW/+*EY(ZMM3O?B["&:^3Z
M$,WG)&8WONZR('@:^30V TSCQ:<AF<&W/\"V0[L<SH+N'N-*[)UY_N4^(*,V
MN'7 (VM*#-MX]_Z/8\/6N%NTN,2</J$I"<F=#QN\B\]#LF>:80QG#7>/:26V
M3-]]6BALV6$' V)_QJ&0J[M#]X05VW*X-\D6BX#,5[)0]$H;EI@PLZ^QQT/T
M2ZI..]4GAV;T-$5$D'7I5$]36DQ/W1M#Z0=^BN.GU5.\+X/:[IGUIM3G>]5W
MCFEEKLO= 7 M6CYQ@W''.<G5Y-N 5,O@/,+=8UR)>ME=I+9KVN6P9,-'J!W=
M:E7M["HZ<+*ZX;Y^6L5@)46R:JX<68,J:K3<W\DN@\Z)0HEVLR53/]*ET%)]
MQN91U_*990+23F5^.:-X<YGDXQ6SFLG3<WZ&<$WS0_ !K\ET/K ,5+^0(&@T
MF\[ I8'+3>KM#,=S[#XAEI:;9@?N?B'0JE>G[4%%/!R^^KAD9ED,NZUU)L&+
M4$?EZBCVY]0K3\^PAZ*(5,D84MQ)OQ61*JG6D562A"+B2!%]B>;D!1.=YD[C
M4GRWZR);'U(L0+<X5G;W?;>Z&:I6X=<W?W#)WU>R>:0WBTN9+BOZJS@F;WJH
M"D^:K?A;K=QBCZ5G.Q<-R=X3,7P2Y1JME\J/CFVCZBIOM3,'5 1/?<[TLED%
MKZ5Z=J=/_N#J<RT7GWOQTZ-)48)MA)X]MI/GW<E*_;FR>GG;BP'N+!2X9-_K
MDFZ;M2SHH5.C1=XL0U;&VC%%WC1%=NSC2J/M;!8&9)EGJ,9FV49W!FLJE<OG
MG4/'\T  JV8"5-SYG'2J6QW9-%[Z3#8K;1@.*V:V5D<.G5RQZ9@32F[HN1U"
MGTC/FNM"G0/\]981&S6=S\^+MJ)1&B@957<73089G6/9<#*-3L3B*!5,5SX>
MC[A1C-G6,(-U'-.GWOSXF830I(NN@0 D3 CZCM/3RE_5M"9:C\@YBV0?%"S>
MAE3SYRT9\I."61UZ4C"K0T\>8=P-IVGK7G5GFM_&6:;EZ$$80<5Y.ZI<<Z[P
MBCNF<QZ&-TK!/U2!>B?$4E7(8<%WLH2* D$EL96 K$9G645:6D'8G&5$J2HT
MBGS6Q&I]DXT2%]#9KX^=^?Y)+<UW9P_,S5:W'PZ<&^P'HV]4MM M"4F:/]&<
M!T?(>U?DG;]-V)"?%,SJT)."61UZ4KAV>N#:T<;"M2-<.SQL;#5'N':$:^=0
MH;'DL]9_Z9ML-!+=<^A=%;$/[O ^>.-^13,AZLVU4Q IERS'880Z;H9-?_=J
ME0_BIHNZ3@5QTX6;FRY%,I /M*#%Q5_>#>^>BP-;+8-=&SCTGHNJR&.U\FV,
MRLW:LJZ/>]_J[AX-C:>Q=JG5W3V:^G%7<KI$@7VMVI5:/?52D%/F<6OZ&D3%
M?(57"8KNT,%7=H9 AUJN=W2-#O\B.!Y%,)(1_80^Q]%C.ELC1.W7YG;<C:NE
M$;X)7B"QZD?7IY%+L$>P1[!G/[GJTW+=(&2^2SS XG$^G5W'AEV;S"U.?1A-
M>?I@(9>=F8Z02R&7/$ZG]W(Y.(,>93L*%'=M-K=Q]. #?CM$U_ ]HPF)'XB'
M+OY:7AE32&='9B.D4T@GO[/IJW0>8][;B9^J.*UK@L+H(:H>[LII+MG]\0%Y
M/G]]3['M%I+"'N4/XX>DNE%^>-,SZ7$T"1KF3H .B1/N QM45>>.!QU?Q)HU
MF$5LBD7, QLT1=Y=GOIL3&AREN4!W7UCIRF;@IV]8:<UWI,PHX?L[,-V[I=9
M% 1/H^@Q?+57[<2<2N">H_=E*I;I5- @'=(3FFE(VAXTU2)FZIAXJ/:X+Y(^
MWA'2V4U)5W1)Y5?2.TE37=Y=V*FS4*+SG-'4/;LSP9H6=UI:/UG3!P#^-?3(
M@E9O@"YO9T^)[_HX1%=)$L$'5M[IJ&01WI3^=]H]YJIM=')56*HTYM<Z"]:>
M!"4E1["VEZQ5>XL :[^Q=&(14SYIIFM5_"$U4(#W=0!;RTJG(6V7LAT24PS5
MDNQJ)X5MLT4HEHU48D*QY(G/.R&_0V*)KMI5 Q#:9LLIT0D]YJ"J[,M3V K[
M>/.I]5\0-$VVA" (00"=7BV8:3""L#TQX'(LO"7XXS%7V%B7%99+[?!<899L
MJ%K5?$9;C'V#B<8K3\H :M2?_PPLN3.N/_53MYK59+L[@SUGLTXCV;K.DM&U
M:RF?\M179RENWC523,AO&8S&Q\%Y,U^U6SY")!GB),F08 _7[!G@>N\&QT7R
M%7XG(Y("]8:5_9=+H>$YY9;(P,'WC$1^&"&=_,YHH/EA.F.->G9!5]5%#HS:
M@Q&MP5SO=B1#Y,!HG0V:W-(BYC1"H-O<%!DP^L1-U109,+H(6 _,@,$Y:N66
M^&77AM73-G3\3&5<*2-:AQ2:9HPED]][=)VDZ84MFQO>J'IHR9M1[Q!75$TD
M+^"4-;JL]I,S?8!.M>0NZ R@$M>U#\=$ADBRT%/6JHJXB=^;\_8^W^S5C?(H
MX2%=.5(E1=F=!XJ32Z1#8HKN*'OWV)RP1=SMW;ZC-V2C;$<_M$M\0Y4!P$(\
M:E8A"(T?DXM[_KV_U2O:.;6=0F#T,;2PB!*?>HK>QR3 J?] +I?W*]G=RY6W
MBFZ5EU?P%-9(EI:_4C:\!A8#NXD]&:G:.A56?\[B%T!U3T;3F.!?1_@.AOD>
M!X_X*5F?S!Q(7[1N&M#]ZTF74GX_'VLCBU&)+%^R.0XQ^AJZ\H:,-#N2_"[$
M+R0(T(3<SZD?<X2^1'.")E2RJ <37?P<XLSS4^*]0YPLL683"SAC637,8Q(+
M:(X,N^_Z[Y\;LJ-4SE=P2+/ZN/SKHV^*CV7'J4:$VG- !N0NK<6=TTC<].LU
MN_W0X5,4HW1&X/^8$#2'YV<)HH<0'EU9-SAV9\OKX>4'\I4HU3MZ'')=GN])
M_XO@>!3!2$;TTXY[\*\PAYJOG';7%S_MUWS)N*6]6361^;CPD\CS773ES?TD
MR6W[W\JO!FWL6_>IB-;VIGNQ#IN_K4FJL;N8[=D]N5TGH2%IXV:/,SD[&ZQ&
MIPN-\RBG:M/H4L!&-1WX4Y3B8%4!CM $T]U.&L4$7=P<H UW^K ZOLY5Q98L
MM5)P_G8R"$6ZC\"69&N[4V$*30J$ZD20Q=':=#">8>$57?>*ZN5>43I0W_O3
M&]]1%&QIUM2Q+=.P-'OJ$!WKMJU,X4_8(/]63>M-:[[4Q@(M&_.85AO)IRA*
MPR@E"4HC@ T@G G3+&CBSHB7!? %#CTTR1:+@%"'*HZ?8-QW43QG$:$M#U_]
MAV:BCS@.06DFZ#L)"$[(IENWRGHM5&]NB@US72?\)P.RW#WE?_)9A.S[D6K7
MZ&JOMM:NGN6EN5XOURACR[9%I_UWDJ(@2A*2[!@1(9JE&6>@ VJ>#&]^Q$4@
M-/'0HY_.F)?.C>: 1I[^.T%A%(Y<P. 4P+%G0"E%L9\^(9\J99*D\.$!?M%5
ME&RN^T[)X9];ET-'UDPZ[4\9O>WGATD6 \TI04!YS5E6T63F+Q!.4$P644PY
MXD6$\HDRP@TRCZ!"#Q>/ T-QBF;X@2",;H@'>A!V45?> X9&[PE:!#C,GRG>
MI[H1T7<][Z7O*0G)G9_*Y8=+O'.8Y8[^T#2'H=?7'-:9IOD:(A?P+O;AMQ^[
MV3Q)<>B21%I=@/ [3&/LIDF^-A?+_#+4KF'7)0"F[_P07J1Y5F,_^16!#0,^
M>\"L$+B7@#Z+[K:Q_4689%0XY\'&7$>/80(]H.^T+1S'.+QG!K(8UW( R$^@
M!9R+)[Z'68 BH"+G,3-+?E^0$)J+J35%8%WO81S4XJ[.;8Z?4#*CHTKP [-T
M=W$T![GV,I<:83I'=F3 W %NE+"IL&G ;_K-<I:K<_D)_@YJ*0M2.D:,9L '
M%) '$M"W2'B/\PDAV@&=$8[397O+V<GHYY!.,J?))A569[#D4#F#: _ '@G=
MP:*6$-#Z/HBF,*5USLEH120H/9DXH L7+_R4J5Y&+(\]_*X8\O[AS:(HH32$
MH9$%_"%_Z66<.#^,"9Y@.+\3;W1'X%N8>TY3^J(;P6X>AIH"H[(I'1>=#KP
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M!S_^/U!+ 0(4 Q0    ( +DPGEJ>I-@W%Q\  #/_   >              "
M 0    !A,7$R,#(U:'5M86YA:6YC<')E<&%R961R92YH=&U02P$"% ,4
M" "Y,)Y: >]HYO /  #X=@  $               @ %3'P  :'5M+3(P,C4P
M-#,P+FAT;5!+ 0(4 Q0    ( +DPGEKJ01*$8 (  /T&   0
M  "  7$O  !H=6TM,C R-3 T,S N>'-D4$L! A0#%     @ N3">6L- %:L@
M"@  ?54  !0              ( !_S$  &AU;2TR,#(U,#0S,%]L86(N>&UL
M4$L! A0#%     @ N3">6C?S[LNO!@  Y3   !0              ( !43P
M &AU;2TR,#(U,#0S,%]P<F4N>&UL4$L! A0#%     @ N3">6C8JI%U;+@
M>LL! !P              ( !,D,  &AU;2TR,#(U<3$X:WAE>#DY>#%B<FEE
M9BYH=&U02P$"% ,4    " "Y,)Y:6U A2/.*  #B#0H 'P
M@ ''<0  :'5M+3(P,C5Q,3AK>&5X.3EX,F1E=&%I;&5D+FAT;5!+!08
.!P ' .,!  #W_      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>hum-20250430_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="hum-20250430.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0000049071</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-04-30</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Humana Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">1-5975</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">61-0647538</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">500 West Main Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Louisville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">KY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">40202</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">502</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">580-1000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">HUM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
